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ABSTRACT 
 
 
 Introduction: Papanicolaou screening is the standard of care for the detection of 
abnormal cervical cells. Early detection and treatment of cervical neoplasia depends on 
the accurate interpretation of the cytologic sample. Diagnosis of dysplasia is made by 
histology interpretation to confirm the results of cytology screening.  Cervical cells are 
susceptible to change as a result of hormonal exposure, and this has the potential to affect 
cytologic interpretation. Cervical cells may be exposed to exogenous progesterone if the 
woman uses injectable depot medroxyprogesterone acetate or a progesterone intrauterine 
device. Previous study results have been inconsistent regarding the effect of progesterone 
on relationship between cytology and histology interpretation. The purpose of this 
exploratory study was to examine the accuracy of cervical cytologic findings in women 
who were using either one of two forms of progesterone only contraception, depot 
medroxyprogesterone acetate injection or the progesterone IUD, as compared to women 
who either used a non-hormonal form of contraception or no contraception. Accuracy, for 
the purposes of this study, was defined as the association between cytology interpretation 
and histology interpretation. A secondary purpose of the exploratory study was to 
investigate whether the length of time of progesterone exposure had an effect on the 
association between cytologic and histologic findings.  
 
 Methods: A de-identified synthetic derivative database was used for this study in 
which cytology and histology results from 180 women were analyzed. Three groups were 
mined from the database: a group using the progesterone releasing intrauterine device 
(IUD, N = 35), a group using the injectable depot medroxyprogesterone (N = 73), and a 
control group of women who used either no contraception or non-hormonal contraception 
(N = 72). Cytology and histology were analyzed for associations as well as for sensitivity 
and specificity. Chi square analysis and logistic regression were the statistical methods 
used to test the associations.  
Results: Cytology and histology results were collapsed into low grade/high grade 
categories. There was a significant association between cytology and histology findings 
(p = .008) among the total group (N = 180). Among subgroups analyzed from low 
grade/high grade perspective, a significant relationship was found between cytology and 
histology among women who had no progesterone exposure (p = .019) and those using 
the progesterone IUD (p = .019). However, there was not a significant association 
between cytology and histology findings in progesterone injection users (p = .790). Thus 
a new outcome variable was then applied for more precise analysis in which each 
cytology/histology relationship was labeled as agree, false negative or false positive. 
Using the new outcome variable (false negative, false positive or agree) there was no 
difference in the association of cytology and histology by progesterone exposure. 
Logistic regression revealed no relationship between length of time of progesterone 
exposure and accuracy of cytologic interpretation.                 
 Conclusion: Although our exploratory study was significantly underpowered, 
findings suggest that the subjects in this study who used either the progesterone IUD or 
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injection had no difference in association of their cytology to histology findings 
compared to women who had no progesterone exposure. What can be derived from the 
study is a basis for comparing varied progesterone delivery systems, as well as format for 
repetition of a similar study in a multi center, multi site study.  There are several other 
forms of progesterone (implant and oral progesterone formulations) which were not 
included in this study which may affect the association between cytology and histology 
results. Further investigation is warranted. 
 
  
 
vii 
 
TABLE OF CONTENTS 
 
Chapter 1. INTRODUCTION ..........................................................................................1 
Overview ..........................................................................................................................1 
Problem Statement ...........................................................................................................2 
Purpose .............................................................................................................................3 
Questions ..........................................................................................................................3 
Significance of the Study .................................................................................................4 
Definitions of Terms ........................................................................................................4 
Assumptions .....................................................................................................................6 
Limitations .......................................................................................................................7 
Conceptual Framework ....................................................................................................7 
Chapter 2. REVIEW OF LITERATURE ........................................................................9 
Overview of Squamous Metaplasia and Human Papilloma Virus as Etiology of 
Cervical Neoplasia ...........................................................................................................9 
Process of squamous metaplasia ..................................................................................9 
Development of squamous intraepithelial abnormality ..............................................10 
Development of glandular abnormalities ...................................................................10 
HPV as etiologic agent in neoplastic development ....................................................11 
Cytopathologic and Histopathologic Characteristics of Cellular Lesions and 
Classification of Abnormal Pap Results .........................................................................12 
Review of abnormal cytology ....................................................................................12 
Atypical squamous cell classification ........................................................................13 
Low grade squamous intraepithelial lesion (LSIL) classification ..............................13 
High grade squamous intraepithelial lesion (HSIL) classification .............................14 
Invasive squamous cell neoplasia classification .........................................................14 
Atypical glandular cell classification .........................................................................14 
ASC-H and LSIL-H classification..............................................................................14 
Description of cervical intraepithelial lesions ............................................................15 
Cervical Neoplasia and Combined Hormonal Contraceptive Use .................................15 
Cervical Neoplasia and Progesterone Use .....................................................................18 
Progesterone Effect on Cervical Cells ...........................................................................19 
Summary of the Chapter ................................................................................................22 
Chapter 3. METHODOLOGY .......................................................................................23 
Overview ........................................................................................................................23 
Research Design .............................................................................................................23 
Sample ............................................................................................................................23 
Setting and Recruitment .................................................................................................25 
Procedures ......................................................................................................................25 
 
viii 
 
Data Analysis .................................................................................................................26 
Coding for Analysis .......................................................................................................26 
Analysis for Individual Questions ..................................................................................31 
Chapter 4. RESULTS ......................................................................................................32 
Research Question 1: What Are the Characteristics (Demographic,  Gynecologic  
and Smoking History) of Four Groups of Women Who Have  Abnormal Cytologic  
Test Results? ..................................................................................................................32 
Characteristics of the sample ......................................................................................32 
Frequency of cytologic and histologic abnormalities .................................................32 
Research Question 2: What is the Relationship between Cytology and Histology  in 
Four Groups of Women with Abnormal Cytology Results? ..........................................38 
Research Question 3: Is There a Difference in the Relationship between Cytology  
and Histology in Four Groups of Women with Abnormal Cytology Results? ..............44 
Research Question 4: Is There a Difference in the Relationship between  Cytology  
and Histology, by Length of Time Using Either Depot Medroxyprogesterone  
Acetate or Progesterone IUD? ........................................................................................44 
Post Hoc Power Analyses ..............................................................................................48 
Chapter 5. DISCUSSION ................................................................................................50 
Use of Contraception Method ........................................................................................50 
Smoking Status ...............................................................................................................51 
Marital Status .................................................................................................................53 
Obstetrical History .........................................................................................................53 
Observed Frequency of Abnormal Pap Results .............................................................53 
Relationship between Cytology and Histology According to  Progesterone  
Exposure .........................................................................................................................54 
Difference in Relationship between Cytology and Histology According to  
Progesterone Exposure ...................................................................................................55 
Relationship between Cytology and Histology, by Length of Time Using either  
Depot Medroxyprogesterone Acetate or Progesterone IUD ..........................................56 
Significance of Findings .................................................................................................57 
Limitations .....................................................................................................................58 
Conclusion ......................................................................................................................58 
LIST OF REFERENCES ................................................................................................61 
VITA..................................................................................................................................71 
 
   
 
ix 
 
LIST OF TABLES 
 
Table 3-1. Categorization of cytology and histology results into collapsed 
categories  ......................................................................................................28
Table 3-2. Definition of agreement between cytology and histology   ...........................29
Table 4-1. Sample characteristics   ..................................................................................33
Table 4-2. Cytology result, cervical histology result, and endocervical curettage 
result by progesterone exposure (n = 180)   ...................................................36
Table 4-3. Crosstabulation of collapsed cytology and histology results for all cases 
(n = 180)   .......................................................................................................39
Table 4-4. Crosstabulation of collapsed cytology and histology results for no 
progesterone exposure (n = 72)   ....................................................................40
Table 4-5. Crosstabulation of collapsed cytology and histology results for 
progesterone IUD (n = 35)   ...........................................................................41
Table 4-6. Crosstabulation of collapsed and histology results for progesterone 
injection (n = 73)   ..........................................................................................42
Table 4-7. Crosstabulation of collapsed cytology and histology result for any 
progesterone exposure (n = 108)   ..................................................................43
Table 4-8. Agreement between cytology and histology results by progesterone 
exposure   .......................................................................................................45
Table 4-9. Agree, false negative, or false positive results between cytology and 
histology by progesterone exposure   .............................................................46
Table 4-10. Tests of the cytology/histology relationship and progesterone exposure   ....47
Table 4-11. Post hoc power analyses  ...............................................................................49
 
1 
 
CHAPTER 1. INTRODUCTION 
Overview 
Cervical neoplasia is the third most common gynecologic neoplasia affecting 
women worldwide.1 Death rates from cervical neoplasia have steadily dropped over the 
past few decades as the use of Papanicolau (Pap) testing to screen for cervical neoplasia 
has become the standard of care.2 The majority of cervical neoplasia deaths in the U.S. 
occur in women who have never been screened, or have not been screened in the five 
years prior to the abnormal Pap result. However, death from cervical neoplasia has been 
noted among women with a recent negative Pap result which occurs as a result of 
detection error in Pap interpretation.3 
 In the early 1990's, human papillomavirus (HPV) DNA was discovered in 
virtually all cervical neoplasia. This has led to numerous studies of the causal relationship 
between HPV and cervical dysplasia and neoplasia and has been widely investigated and 
validated.4-10 HPV is a DNA virus that is sexually transmitted. There are approximately 
30-40 urogenital subtypes of HPV, with types 16 and 18 being implicated as the cause of 
approximately 70% of all cervical neoplasia.11 The high risk subtypes are associated with 
the development of cervical dysplasia/neoplasia; whereas, the low risk subtypes are 
associated only with genital skin lesions.  
Much has changed in the last 25 years in the knowledge of causative factors of 
cervical neoplasia. Screening for cervical neoplasia evolved with the arrival of HPV 
testing as an adjunct to the Pap test. However, Pap screening remains the standard of care 
for the detection of abnormal cervical cells in a woman who has cervical dysplasia or 
cervical neoplasia. Early detection and treatment of cervical neoplasia for many depends 
on accurate cytologic interpretation. The sensitivity of the Pap test has been shown to fall 
within a range of 50-75%.12 A 1999 Agency for Health Care Policy Research review set 
Pap test sensitivity within a range of 51-66% for detection of all grades of cervical 
intraepithelial neoplasia (CIN) and slightly higher for high grade lesions (not exceeding 
70-80%).13 Uyar et al (2003) noted cytologic screening to have a high sensitivity from 
55% to nearly 100% for detecting squamous cell neoplasia.14  
Cytologic screening relies on the subjective interpretation of the sample by a 
pathology professional. Theoretically, any factor which affects the cells contained in the 
sample may also affect the subsequent interpretation of the sample. Exogenous hormones 
affect cervical cellular characteristics.15-17 Exogenous hormones include all hormones to 
which a woman is exposed to in addition to what she produces endogenously.1,18 
Exposure to exogenous hormones may occur in the course of a woman taking either 
contraception or hormone replacement therapy. Cellular effects related to exogenous 
progesterone exposure include crowding of cells, curling of cells, and the presence of 
navicular cells (glycogen filled squamous cells with thickened borders).16 These cellular 
alterations may lead to difficulty with cytologic interpretation, though little research has 
been conducted on the issue.15-17 Progesterone only contraceptive methods are used by as 
many as 19% of women in the United States.19,20 This means that these women may 
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potentially be affected by any phenomenon which exists between progesterone exposure 
and variation in cytologic interpretation.  
Findings to date regarding a definitive effect of progesterone on cytologic 
interpretation are conflicting. Some studies demonstrate a greater number of false 
negative,21 and some a greater number of false positive cervical changes.16 Further 
research is needed to determine the relationship between cytology and histology in 
women using progesterone contraception and whether that relationship differs from 
women not using progesterone contraception. Interpretation rates will be affected if there 
is a difference in the relationship between cytology and histology results in women using 
progesterone contraception. These changes in interpretation rates could have an affect on 
the rate of cervical dysplasia and neoplasia. This study included a control group of 
women using either non-hormonal contraception, or no contraception. This work 
contributes to the existing body of knowledge by comparing groups of women with 
abnormal cytology results who have either no, or varying types of progesterone exposure 
to women with no recent (> 6 months) progesterone exposure. No study to date has 
compared progesterone IUD users to progesterone injection users against a control group 
of women without recent progesterone exposure. This study focused on the relationship 
of cytology to histology in women using two different progesterone only contraception 
methods compared to a control group not exposed to progesterone. Addressing this 
question will inform us if progesterone and progesterone delivery method affects cervical 
cytologic interpretation and ultimately the diagnosis of cervical neoplasia.  
Problem Statement 
Cervical neoplasia screening and diagnosis begins with, and is dependent upon, 
the accurate interpretation of cytologic specimens. Women who have abnormal cytologic 
screening results undergo a colposcopy with possible cervical biopsy and/or endocervical 
curettage. This is the standard of care for follow up once a woman has an abnormal 
cytologic screening result. Colposcopy is an invasive procedure for which women 
experience a high level of anticipatory anxiety over the potential pain involved, 
outcomes, and lifelong implications.22-24  
Any effect that progesterone may have on the accuracy of cytologic interpretation 
has far reaching effects on women whose cytologic samples may be erroneously 
interpreted. Women would undergo an unnecessary and costly colposcopic procedure 
should progesterone exposure lead to false positive results. Women who do not truly need 
colposcopy but who are referred for colposcopy based on abnormal cytology are at risk 
for physiologic and psychological morbidity. Women who undergo colposcopy 
experience negative mental health effects as far as two years after having received the 
abnormal cytologic screening result.25,26 
The economic effect of women undergoing unnecessary colposcopy is also an 
important issue that cannot be underestimated. An estimated range of 10-30% of the 50 
million cytologic annual screening tests done in the U.S. return with a result of atypical 
squamous cells of undetermined significance (ASCUS).27,28 Considering that 1% of these 
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ASCUS results require further colposcopic work up, between 25 million and 75 million 
dollars annually are used for women undergoing unnecessary colposcopy and/or biopsy. 
By identifying any association in women using progesterone only contraception and a 
variance rate in interpretation, the manner in which high risk HPV infected women 
should be counseled regarding contraceptive choice will be affected.  
A false negative cytologic screening result (where pathologic markers in the 
cytologic sampling are misinterpreted as normal) could mean that women with advanced 
cervical pathology may go undetected and develop cervical neoplasia. Undetected high 
grade squamous epithelial lesions are at the greatest risk of evolving into cervical 
neoplasia over time. A consensus in the literature suggests that, left undetected, greater 
than 50% of women with low grade squamous epithelial lesions go on to progress to 
cervical intraepithelial neoplasia III (CIN III) within a period of 5 years.27 In summary, 
exogenous progesterone may lead to either false-positive or false-negative results on 
cytologic screening. Both results can have important psychological and physical 
consequences, including death due to delayed cancer diagnosis. 
Purpose 
The purpose of this exploratory study was to examine the accuracy of cervical 
cytologic findings in women who were using either one of two forms of progesterone 
only contraception, depot medroxyprogesterone acetate injection or the progesterone 
IUD, as compared to women who either used a non-hormonal form of contraception or 
no contraception. Accuracy, for the purposes of this study, was defined as the association 
between cytology interpretation and histology interpretation. A secondary purpose of the 
exploratory study was to investigate whether the length of time of progesterone exposure 
had an effect on the association between cytologic and histologic findings.  
Questions 
1.  What are the characteristics (demographic, gynecologic, and smoking history) of 
four groups of women who have abnormal cytology test results? 
1a. Those who use the progesterone IUD. 
1b.  Those who use depot medroxyprogesterone acetate. 
1c. Those who use either no contraception or a non-hormonal contraceptive 
method. 
1d.  Those who use either the progesterone IUD or depot medroxyprogesterone 
acetate. 
2.  What is the relationship between cytology and histology in four groups of women 
with abnormal cytology results? 
2a. Those who use the progesterone IUD. 
2b.  Those who use depot medroxyprogesterone acetate. 
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2c. Those who use either no contraception, or a non-hormonal contraceptive 
method. 
2d.  Those who use either the progesterone IUD or depot medroxyprogesterone 
acetate. 
3.  Is there a difference in the relationship between cytology and histology in four 
groups of women with abnormal cytology results? 
3a.  Those who use the progesterone IUD. 
3b.  Those who use depot medroxyprogesterone acetate.  
3c.  Those who use either no contraception or a non-hormonal contraceptive 
method. 
3d.  Those who use either the progesterone IUD or depot medroxyprogesterone 
acetate. 
4. Is there a difference in the relationship between cytology and histology, by length 
of time using depot medroxyprogesterone acetate or the progesterone IUD? 
Significance of the Study 
The knowledge that there may be an association between progesterone only 
contraceptive methods and altered interpretation of the cytologic screening test is 
important. Cytologic screening is crucial in detecting cervical dysplasia. Women infected 
with a high risk HPV type need to be informed of the risks associated with using 
progesterone only contraception and potential for inaccurate cytologic screening 
interpretation should an association exist cytopathology professionals interpreting the 
cytologic sampling would also need to be aware of the woman's use of a progesterone 
only product, and how that may affect the characteristics of the cervical cells in the 
sampling they are interpreting. In addition, improved screening techniques could be 
developed to better delineate cervical cells with non-pathologic cytologic changes as a 
result of progesterone, from those with cellular changes which are truly of consequence.  
Definitions of Terms 
Terms to be defined include Papanicolaou screening, combined oral 
contraception, colposcopy, progesterone intrauterine device, and depot 
medroxyprogesterone acetate. Terminology used to describe collapsed cytology and 
histology groups includes low grade and high grade, and is defined. Other terms include 
all terminology used to describe abnormal cervical cytology (atypical squamous cells of 
undetermined significance (ASCUS), atypical squamous cells of undetermined 
significance, cannot rule out high grade (ASC-H), low grade squamous intraepithelial 
lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), squamous cell 
carcinoma, and atypical glandular cells (AGC). The terminology used to define abnormal 
histology includes: cervical intraepithelial neoplasia (CIN I, II, or III), squamous cell 
neoplasia in situ, invasive squamous cell carcinoma, adenocarcinoma in situ, and invasive 
adenocarcinoma.  
 
5 
 
1. Papanicolaou screening, or Pap test
currently available for cervical neoplasia. Exfoliated cervical cells are collected 
and prepared for microscopic evaluation by a pathology professional.29 The 
terminology of cytologic screening refers to screening achieved via collection of 
the Pap test. 
, is the primary cytologic screening test  
2. Combined oral contraception methods (COCs)
both the hormonal components of estrogen and progesterone. The hormones are 
released from the oral preparation at either a constant rate (monophasic 
preparation), or at varying rates (biphasic/triphasic preparations) through the 
entire monthly cycle.30 
 are those which contain  
3. Colposcopy
cytologic screening test result. This involves the application of a dilute solution of 
acetic acid to the cervix, after which a colposcope (a high power microscope) is 
utilized to visualize cervical lesions. A histologic sampling, or biopsy, may or 
may not be collected at the time of colposcopy, based on the clinical judgment of 
the colposcopist.  
 is the procedure for examining the cervix after an abnormal  
4. Progesterone intrauterine device
that releases the progestin levonorgestrel on a steady basis directly into the uterine 
cavity.  
 is an intrauterine system of contraception  
5. Depot medroxyprogesterone acetate
(150 milligrams per dose) that is long acting, requiring injections every three 
months. 
 is an injectable form of progesterone  
6. Low grade cytology
ASCUS no HPV result, ASCUS HPV positive, ASCUS HPV negative, and LSIL. 
 includes the following cytology classifications:  
7. High grade cytology
 HSIL, AGC, ASCUS-H, and LSIL-H. 
 includes the following cytology classifications:   
8. Low grade histology
9. 
 includes the following histology classifications: Cervicitis, 
 CIN I. 
High grade histology
III, CIS, invasive neoplasia, adenocarcinoma. 
 includes the following histology results: CIN II, CIN  
 All of the following cytologic interpretation categories are assigned through the 
Bethesda system of classification which is the systematic method of cytologic test 
abnormality classification currently in use in the U.S.31   
1. Atypical squamous cells of undetermined significance (ASCUS) 
designation assigned by pathologists to cytologic screening samples when there 
are cervical cells with abnormal features that result in an unclear impression as to 
whether they are inconsequential, or problematic in nature.31 Atypical squamous 
cells of undetermined significance cannot rule out high grade (ASC-H) is a 
cytologic designation assigned to cytology samples where immature squamous 
cells with properties similar to high-grade dysplasia are noted.31 The defining 
pathologic sign for dysplasia is abnormality of the cell nucleus.  
is a  
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2. Low grade squamous intraepithelial lesion (LSIL
assigned to cytologic samples where the cell nucleus is at least three times larger 
than that of normal cells. There are also other abnormal morphologic criteria 
present in cytology samples designated as LSIL, such as irregular nuclear 
shaping, wrinkling of the cell membrane, and multiple nuclei.31  
) is the designation  
3. High grade squamous intraepithelial lesions (HSIL) 
cellular features that may be similar to samples that are LSIL, with the addition of 
a greater nucleus to cytoplasmic ratio.31 
have some abnormal  
4. Atypical glandular cells (AGC)
glandular cells in the cytologic sample contain cellular abnormalities that cannot 
be definitively diagnosed as either benign, premalignant, or malignant.31  
 is the designation assigned when the  
5. The cervical intraepithelial system (CIN)
for gradation of histologic samples collected at colposcopic exam. The level of 
CIN is assigned according to the degree of abnormal cellular proliferation present. 
CIN I is assigned to histologic samples where a mild degree of dysplasia, or 
abnormality, is noted. CIN II histologic samples are consistent with a moderate 
degree of dysplasia. CIN III histologic samples are designated as such because 
they denote characteristics of severe dysplasia and/or neoplasia in situ.31 
 is the grading system reserved  
6. Squamous cell neoplasias
cells. Here, the term refers specifically to the squamous cells of the cervix. 
Whether it is contained within the cell (in situ) or has spread beyond the cell 
borders (invasive) is designated within the histology report.  
 the form of neoplasia which affects squamous  
7. Adenocarcinom
 malignancy originating in the glandular epithelium of the cervix.29 Whether it is 
contained within the cell (in situ) or has spread beyond the cell borders (invasive) 
is also designated within the histology report.  
a is designated to histology sampling that indicates a  
Assumptions 
 This study had multiple assumptions:  
1. The evidence describing the relationship between exogenous progesterone  
and subsequent effect on cervical cells was salient and would support why a 
difference in interpretation accuracy may exist.  
2. The mode of data measurement and subsequent analysis adequately  
captured what was known about the key concepts. 
3. Any evidence gleaned as a result of the study method and data analysis  
would be adequate to either support or deny any relationship between 
progesterone use and accuracy of cytologic interpretation. 
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4. The delivery system and the dosage of the exogenous progesterone could  
 have had specific influence on hormonal cellular effects, underscoring why two 
methods of progesterone delivery were included in the study.  
Limitations 
A primary limitation of this study was threat to internal validity. There was an 
inability to control for either the same practitioners collecting the samples, or the same 
pathology professionals interpreting the samples. The study undertook the examination of 
existing cytologic and histologic reports contained within the subject's records. Another 
limitation of the study involved the use of an electronic database used for the data. Data, 
particularly demographic data, may have been missing from patient records. In addition, 
patient records rely on the information first being correctly entered by patient care 
providers. However, the advantage of using this large database was for this particular 
study was the large number and heterogeneity of the subjects.  
Conceptual Framework 
The framework underpinning this study included the key concepts of cervical 
cells that exhibited changes that occurred as either the result of progesterone exposure, 
HPV exposure, or both. Other key concepts included exogenous progesterone, either in 
the form of depot medroxyprogesterone acetate or the progesterone IUD, cytologic 
interpretation, and histologic interpretation. The relationship among the key concepts and 
the cytologic and histologic interpretation of the cervical cells was the focus of this study. 
The state of the science includes the most prominent key variable of cervical cytology 
interpretation. The development of squamous intraepithelial abnormalities follows the 
course of the host first being infected with a high risk type of HPV after which the basal 
cells of the stratified epithelium are affected first.32 Lower levels of dysplasia 
demonstrate squamous cells wherein HPV produced proteins have caused cellular death, 
exfoliation and disintegration.  Actual integration into the host cell's genomic structure is 
noted with higher level dysplasia. This integration leads to further production of 
neoplastic proteins which then promote change of immature basal and parabasal cells. 
The dysplastic basal and parabasal cells have the opportunity to spread and invade 
surrounding endocervical glands though the basement membrane maintains integrity.31 
Invasion of the neoplasia into surrounding tissue will occur once the basement membrane 
is compromised.  
Exogenous progesterone changes cervical cellular characteristics.7,17 Cellular 
characteristics which have been associated with the effect of progesterone exposure 
include curling or crowding of squamous cells, destruction of cells, and unusual 
morphology to cells (navicular or classically called "boat shaped").16 This cellular 
phenomenon caused by progesterone has the potential to affect the cytological 
interpretation of the cells. Progesterone is thought to promote atrophy of the epithelial 
cells as well as to decrease the cellular maturation pattern.5,33 The resultant atrophy of the 
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squamous epithelial cells and the change in expected maturational progression can mimic 
changes which are specific to cellular dysplasia, without actually being dysplastic.  
The cytologic interpretation of the cervical cell specimen dictates whether a 
woman is referred for colposcopic examination, and this means that the effect of 
exogenous progesterone as a potential variant in cytologic accuracy is important. Very 
little research exists on the issue of cervical cell exogenous progesterone exposure and 
the relationship to cytologic interpretation. Cytologic interpretation of cervical squamous 
epithelium via the Pap test has a sensitivity of 80% (range of 51-83%),31 (50-75%),12 and 
a specificity of 95% for detection of abnormal cervical cytology. Cytology is part of the 
current standard for screening for cervical dysplasia.34 The basis for cytologic screening 
is the premise that abnormal cervical squamous epithelium cells and neoplastic 
endometrial cells are shed into the secretions of the cervix and vagina. These secretions 
are then transferred to a medium, whether in liquid or fixed onto glass slide, and then 
examined by a pathologist.35 One of the errors that can occur with cytologic screening 
accuracy is failure of correct cellular interpretation.14 Interpretation of the cervical 
cytology precedes recommendation for colposcopic examination and histologic 
interpretation of cervical tissue collected at the time of colposcopy.  
Histologic interpretation of the tissue submitted at colposcopy is the diagnostic 
measure used to determine the underlying cause of the abnormal cytologic screening. The 
colposcopist identifies abnormal visual features and decides whether biopsy is indicated. 
The colposcopist's main goal is that of not letting cervical neoplasia go undetected.36 
Stafl and Mattingly (1973) documented the diagnostic accuracy of colposcopically 
directed biopsies as equal to that of tissue obtained by cold knife cone biopsy.37 The 
cervical biopsy done under colposcopy has now become the standard of care for the 
diagnosis of cervical dysplasia.  
 The concept of relationship between histology and cytology is important in that 
the cytology results direct subsequent histological examination. The ASCUS/LSIL Triage 
study (or "ALTS," as it is referred to) of 1995-2001 set the standard for much of what is 
known about the relationship between abnormal cytology and subsequent histology.13 
Treatment of cervical dysplasia and neoplasia is determined by the histology result, thus 
clinicians and researchers must understand the relationship between cytology and 
histology. Further, factors that may affect that relationship need to be well understood. 
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CHAPTER 2. REVIEW OF LITERATURE 
Five major areas of the literature will be reviewed. The first section reviews the 
physiologic process of both normal and abnormal squamous cell metaplasia. The 
literature on HPV is then reviewed, as HPV persistence is the main known etiologic agent 
for development of cervical dysplasia and cervical neoplasia. The second section is a 
discussion of the pathologic characteristics of each of the types of abnormal cytologic 
classifications. The section also reviews cytologic classifications, according to the 
Bethesda system31 of classification currently in use. Comprehension of the classification 
system is critical to the understanding of cytologic abnormalities are classified. The third 
section addresses the literature on cervical neoplasia and combined hormonal 
contraceptive use (contraception that contains both of the hormones estrogen and 
progesterone). The rationale for reviewing the literature encompassing the use of both 
estrogen and progesterone is that the majority of literature on the effect of exogenous 
hormones lies in this arena. The fourth section is an overview of the literature on cervical 
neoplasia and progesterone use and lays the foundation for the final section which 
focuses solely on the existing literature dealing with the progesterone effect on cervical 
cells. An understanding of the progesterone induced changes which occur in cervical 
cells is critical to comprehension of how cellular changes can affect cytologic 
interpretation. 
Overview of Squamous Metaplasia and Human Papilloma Virus as Etiology of 
Cervical Neoplasia 
Cervical neoplasia is the third most common gynecologic neoplasia affecting 
women worldwide.1 Invasive squamous cell neoplasia of the cervix is preceded by 
identifiable cellular precursors.38 The human cervix is composed of stratified squamous 
cells as well as columnar cells, with the major portion of the cervical portio lined with the 
stratified squamous cells. Metaplasia constantly occurs as the columnar cells become 
stratified squamous cells, and glandular cells of one type evolve into different types of 
glandular cells. Cervical metaplasia is not completely understood but is thought to be 
initiated by the move of the original squamocolumnar junction (SCJ) onto the cervical 
portio and the exposure of columnar cells to the acidic vaginal environment. The SCJ is 
the area on the cervical surface where the columnar cells of the internal os of the cervix 
meet the stratified squamous cells of the ectocervix, and the former SCJ moves outward 
on the surface of the cervix as new cells continually form. The area between the "old" and 
the "new" SCJs is called the transformation zone and is where these two types of cells 
meet. Cervical metaplasia occurs within the transformation zone and is the most likely 
site for dysplasia to also occur.31  
 
Process of squamous metaplasia 
The process of squamous metaplasia refers to the naturally occurring and benign 
evolution of cells of the squamous epithelium. There are multiple layers to the squamous 
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epithelium and each layer has specific cell and protein types. Basal, or basement 
membrane cells, form the deepest layer. The next layer up is the stratum and contains the 
parabasal cells which have a differentiation function. An important difference between 
the basal and parabasal cells is that the parabasal cells have proliferating nuclear antigen 
(PCNA) as well as protein RB (pRB). Basal cells do not contain PCNA, which keeps 
them in a quiescent state as opposed to one of active division.31 Reserve cell hyperplasia, 
is a sole layering of subcolumnar reserve cells and also occurs along with these cellular 
processes. In summary, this ongoing simultaneous activity of varied types of cells, in 
various stages and speeds of evolution, at various levels of the epithelium, is a function of 
normal squamous epithelium.39 There is concomitant deterioration of the existing 
columnar cells in the process of reserve cell propagation. The last step in the metaplastic 
process is that of the endocervical glands undergoing metaplasia and joining the 
superficial squamous cells.31 The SCJ has great potential for neoplastic cells to develop 
as the immature metaplastic squamous cells become mature metaplastic squamous cells, 
replacing columnar cells, and later becoming stratified squamous cells.40 Both the rate 
and the degree of metaplasia have been singled out as predictors for dysplasia 
development.41 Other factors which aid in the process of squamous metaplasia include: 
changes in hormonal balance (such as with menarche, pregnancy, and menopause); 
chronic inflammation; and pH changes.31  
 
 
Development of squamous intraepithelial abnormality  
The development of squamous intraepithelial abnormalities occurs with the host 
being infected with a high-risk type of HPV, after which the basal cells of the stratified 
epithelium are primarily affected first.32 It is not merely the presence of HPV infection 
that is the impetus for cervical dysplasia, but the persistence of the HPV infection. 
Cervical dysplasia is known to be multifactorial, with risk factors increasing the 
likelihood of development of dysplasia in a woman infected with HPV.4 Cervical 
intraepithelial neoplasia I (CIN I) lesions demonstrate squamous cells wherein HPV 
produced proteins have caused cellular death, exfoliation, and disintegration. With CIN II 
and CIN III lesions, actual integration into the host cell's genomic structure is noted, 
which instigates further production of neoplastic proteins which then promote change of 
immature basal and parabasal cells. The dysplastic basal and parabasal cells have 
opportunity to spread and invade surrounding endocervical glands, though the basement 
membrane maintains integrity.31 
 
Development of glandular abnormalities  
Glandular lesions usually arise in the transformation zone, though they may occur 
anywhere in the endocervical canal. The reactive cellular changes that occur with 
glandular abnormalities are similar to the changes that occur in squamous metaplastic 
cells. Glandular epithelium can retain its original state throughout the cell's life; it can 
convert to glandular neoplasia, convert to normal squamous epithelium, or become a 
squamous neoplasia, via the process of atypical metaplasia. The evolution of the various 
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types of glandular cells can occur simultaneously; therefore, it is not unusual to see 
mixed disease wherein adenocarcinoma coexists adjacent to a squamous cell lesion.42  
The pathophysiology of normal glandular cell conversion to neoplasia is not well 
understood.  Abnormal glandular cell development is likely a multifactorial event which 
occurs with the presence of particular persistent HPV types in combination with vaginal 
pH changes, hormonal changes, or cellular trauma. Squamous cell metaplasia, whether 
normal or abnormal, is not the stimulus for glandular disease.31 There is disagreement as 
to whether glandular abnormality is connected to reserve cell hyperplasia, which has also 
been implicated in the development of squamous cell neoplasia. Cytokeratins 6 and 16 
appear to be more prevalent in squamous metaplastic cells that become dysplastic, while 
cytokeratins 4, 10, 13, and 14 are more commonly expressed in squamous cells that do 
not become dysplastic.31 The hypothesis of atypical glandular cell formation is that 
reserve cells,beneath the columnar epithelium become hyperplastic through a process 
stimulated by both the presence and persistence of high risk HPV, in particular types 16 
and 18.43 Pathologists note atypical glandular cells in either stratified or pseudostratified 
formation which may be single or multilayered upon examination of cytologic 
sampling.31 Glandular lesions generally exhibit the following characteristics under 
cytopathologic examination: 1) specific clustering of glandular epithelium with 
hyperchromatic nuclei, 2) fragmented nuclei, and 3) an elevated mitotic index.38  
Cytologic screening results of atypical glandular cells (AGC) are fairly 
uncommon (0.5- 1%) and between 17% and 59% of women with this result have 
oncogenic lesions present.44 In contrast, ASCUS cytologic screening results are the most 
common cytologic screening abnormality reported, yet only 5-10% of women with an 
ASCUS result actually have a high grade lesion (CIN II or greater) present. 
Adenocarcinoma, either invasive or in situ, will be found in approx. 5-10% of women 
with AGC cytology screening results. A larger proportion of cervical neoplasias with an 
AGC screening result will be found to have adenocarcinoma/adenosquamous findings on 
the histological exam.45  
 
HPV as etiologic agent in neoplastic development  
HPV plays a central role in the development of cervical neoplasia. At least 50% 
of sexually active persons will be infected with at least one type of urogenital HPV 
during their lifetime, and some estimates extend that to as high as 80%.46 The presence of 
persistent HPV is a necessary but not sufficient component for the development of 
cervical dysplasia and neoplasia. Only a very small proportion of women infected with 
HPV develop cervical neoplasia. This fuels the assumption that cervical neoplasia is a 
multifactorial phenomenon. Numerous studies have consistently demonstrated HPV 
DNA in the cervical specimens of women with cervical neoplasia 90-100% of the time, 
compared to a prevalence of 5-20% in studies with equal controls.47  
There are over 100 various types of HPV, and as many as 40 affect the human 
urogenital tract. Types 16 and 18 are implicated as the cause of approximately 70% of all 
cervical neoplasias.11 Approximately 13 strains are labeled as high risk types because 
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they increase a woman's risk of cervical neoplasia. Low risk types, particularly 6 and 11, 
are the major cause of visible HPV lesions of the anogenital tract, but do not increase a 
woman's risk for cervical neoplasia. The largest demographic group of newly infected 
females are young women below the age of 25 at coitarche.48 Infection in young women 
tends to be of a transient nature, with persistent infections developing in approximately 5-
10% of those infected. The persistence of the HPV infection is thought to be the impetus 
for pre-cancerous and cancerous lesions more so than just the presence of HPV.49,50 
There is question in the literature as to whether HPV viral load has a positive 
association with any of the grades of cervical intraepithelial neoplasia. Huang et al. 
(2008) found HPV DNA load, as detected by hybrid capture, was not consistently 
associated with cervical lesion severity.51 In contrast, Bosch et al. (1993) noted higher 
viral HPV loads were associated with lesions of greater severity. Ho and colleagues, in 
their work looking at messenger RNA levels and relationship to severity of cervical 
neoplasia, suggested that the transcriptional activity of high risk HPV types is varied.52 
Specific high risk HPV types (16, 18, 52, and 58) are the catalyst for host cell 
chromosomal instability to a variable extent, depending on the amount of high risk HPV 
E6 messenger RNA.53 Thus, Ho and colleagues concluded that quantifying levels of HPV 
E6 mRNA may in fact be a superior method of measuring dysplastic severity.52 
The genomes of high risk HPV are thought to be confined to the basal cells of the 
epithelium following infection.54,55 This is where the HPV oncogenes gain access into the 
S-phase of cellular mitosis and replication of the virus is activated.56 Of note, genetic 
expression during this mitotic phase is of no pathologic consequence as the changes are 
occurring among cells that are shed during the continuous cycling of the squamous 
epithelium.57 The persistence of HPV infection is required for the eventual progression to 
neoplasia. High risk types of HPV maintain persistence via their involvement in the 
mitotic phase as described. When this occurs, the normal order of cellular evolution and 
maturation is disrupted throughout all of the layers and evolves to abnormal cell 
production.58 The degree of HPV expression within the cervical cells is a crucial 
determinant in the severity of the cervical dysplasia. For instance, basal cell oncogenic 
expression is noted completely through all of the cellular layers in CIN II and higher 
lesions. Conversely, there is an inhibition of basal oncogenic expression throughout all 
cellular layers in CIN I lesions.59-61  
Cytopathologic and Histopathologic Characteristics of Cellular Lesions and 
Classification of Abnormal Pap Results  
 
Review of abnormal cytology  
Microscopic examination of the cytologic sample collected from the cervix via 
the cytologic screening test involves detection of certain cellular characteristics including 
aberrations of the nuclear chromatin, size and shape of the nucleus in relation to the 
cytoplasm, and keratinization.27 The critical feature in identifying dysplasia is altered 
nuclei formation. Dysplastic cells have an enlarged nucleus with an irregular nuclear 
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membrane and pronounced nuclear chromatin. LSIL lesions exhibit these changes in the 
mature epithelial cells. In contrast, HSIL lesions exhibit these changes in the immature 
cells (basal and parabasal).31 
 Cytologic screening characteristics of LSIL include modification of the epithelial 
thickness, atypical nuclei in upper layers of the epithelium, no atypia in the parabasal and 
basal layers, and cellular polarity maintenance. Other characteristics which may be 
present include binucleated cells with larger than normal hyperchromatic nuclei, and 
irregular halos of cytoplasm.38 Differentiating LSIL from HSIL includes the 
identification of cells in the lower epithelial layers which have a high nucleus to 
cytoplasm ratio with chromatin that is coarse in appearance. Other cellular characteristics 
which distinguish LSIL lesions from HSIL lesions include fewer mitoses among the cells 
in LSIL lesions, and those abnormal cells present limited to parabasal and basal cellular 
layers. Cells in LSIL lesions demonstrate cell polarity perpetuation, atypical nuclei absent 
from lower layers, and lack of mitotic figures.38 
 
Atypical squamous cell classification  
 Atypical squamous cells may develop in response to stimuli in the vagina 
(intercourse, infection, tampon use) that are completely unrelated to either HPV infection 
or existing dysplasia. Cellular changes that occur in response to HPV infection may be 
classic (larger than normal, irregularly shaped nuclei within ballooning cytoplasm, or 
with a perinuclear halo). HPV effect may also produce less distinctive cellular effects.31 
ASCUS is the likely cytologic screening interpretation when cellular changes are noted, 
which are not certain markers for HPV infection, or when the number of abnormal cells is 
very few. The risk of having a dysplasia is very low for women who test out with 
ASCUS, HPV negative. HPV positive women with ASCUS results are 12.5-23 times 
more likely to actually have CIN II, III than women who are not HPV positive.62 ASCUS 
is the most common cytologic result. Approximately 2-3 million women annually have 
an ASCUS cytologic screening result.63,64  
 
Low grade squamous intraepithelial lesion (LSIL) classification  
A cytologic screening result of LSIL would indicate cells that have either a 
polymorphonucleocytenucleus or nuclear size that is three times that of normal and 
abnormal in shape, with irregular membrane consistency. The nucleus of these cells is 
confined to approximately one third of the cellular area. The cellular abnormalities are 
limited to the most superficial of cells, and there is a definitive border between the 
cellular cytoplasm and the perinuclear clearing within the cell.64,65 Incidence rates for 
LSIL cytologic screening results have been quoted from 1.6% to 7.7%.66 Low risk lesions 
have a very high rate of regression to normality, averaging 57%, with a persistence of 
32%, and a progression rate to CIN III of 11%.Total risk of progression to invasive 
neoplasia is only 1%.67,68  
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High grade squamous intraepithelial lesion (HSIL) classification  
Cytologic screening results of HSIL have some common nuclear characteristics 
seen in LSIL cytology specimens and some distinct differences. The nuclei of HSIL cells 
occupy much more cellular area than the LSIL cell nuclei. Approximately half of the total 
cellular area in HSIL specimens is occupied by nuclei, as compared to one third for the 
LSIL specimens. The nucleus to cytoplasm ratio, therefore, is greater in the HSIL cell 
than it is in the LSIL cell. Cells of an HSIL sample are also geometrically arranged side 
by side in single fashion, or in groups.65 HSIL has an incidence of 0.45%.66 Lesions that 
result in an HSIL cytologic screening result are generally of CIN II or III or greater in 
severity. Regression of CIN II lesions has been calculated at 40%, persistence at 40%, 
progression to CIN III 15% and progression to invasive neoplasia 5%. CIN III lesions 
have a regression rate of 33%, persistence of 55%, and rate of progression to invasive 
neoplasia of greater than 12%.69 
 
Invasive squamous cell neoplasia classification  
There must be basement cellular membrane and encroachment into the stroma 
lying beneath the basement membrane to classify a cytologic sample as invasive 
squamous cell carcinoma. There is visible evidence of cellular degradation within the 
sample, as well as inflammation and bleeding.70 Abnormal cellular shape is also 
characteristic of this cytologic result, with enlarged nuclei, which also exhibit coarse 
chromatin.65  
 
Atypical glandular cell classification  
Cellular characteristics of atypical glandular cells include indiscriminate cell 
borders and cellular spacing, enlarged nuclei, varying in shape and size with coarse 
chromatin. There is also a higher nuclear to cytoplasm ratio.71  
 
ASC-H and LSIL-H classification  
Both ASC-H and LSIL-H have the H designation added on to denote that the 
sampling exhibits characteristics of the original cytologic category named, with the 
additional caveat that there are cellular characteristics which are also high grade in 
nature. However, there are insufficient cellular characteristics present to designate the 
specimen as HSIL. ASC-H and LSIL-H both present a greater risk for cervical neoplasia 
development than either ASCUS or LSIL, but less risk than a HSIL cytologic screening 
result.31 ASC-H has an incidence of only 0.27%-0.6%.72  
 
 
15 
 
Description of cervical intraepithelial lesions  
A woman undergoes colposcopic examination following an abnormal cytologic 
screening test. At the time of colposcopy, a biopsy may or may not be indicated, 
according to the visual findings of the colposcopist. Koilocytes (cells which are the end 
product of degraded mature squamous cells and are permeated with HPV particles) are 
identified in CIN I lesions. The koilocytes are confined to the anterior layers of the 
squamous surface and have the enlarged nuclei, prominent chromatin and 
characteristically irregular or "wrinkled" appearing nuclear membrane - all of which are 
characteristics noted in those cytologic results of LSIL. Cells may also be multi-
nucleated, and the cytoplasm immediately adjacent to the nuclei has a clear appearance 
due to the agglomeration of the cytoplasm towards the edge of the cells which casts a 
halo appearance around the nuclei.68,73  
Histologically, CIN II lesions are distinguished from CIN I lesions by the extent 
of propagation of abnormality extending to the parabasal and basal cell layers.68,74,75 
Irregularly shaped, enlarged nuclei are also noted, with darkened and grainy chromatin 
filling the nuclei. There is variation among nuclear size, and some degree of nuclear 
overlay may be present.31 Invasive neoplasia presents with the interrupted basement 
membrane with the phenomenon of "nests" of malignant cells evidenced throughout the 
stromal cell layer. Prominent, oversized nuclei and course chromatin with accompanying 
inflammation is also characteristic.65  
Cervical Neoplasia and Combined Hormonal Contraceptive Use 
 The cellular effect of exogenous combined progesterone and estrogen hormonal 
contraception (COC) has been studied with confounding results.76-78 The mechanism 
whereby exogenous combined contraceptive use may increase a woman's risk for cervical 
neoplasia is thought to be via binding of the steroid contraception to particular DNA 
sequences in the transcriptional areas of the HPV DNA.1 The elevated levels of 
endogenous progesterone and estrogen in women taking COCs may increase risk for 
proliferation of abnormal cells via indirect affect on the HPV infected epithelial cells.79 
The transformation zone of the cervix has high affinity for sex hormone regulation, and 
in the presence of HPV and estrogen has been shown to be particularly sensitive to 
squamous lesion development.80 Sex hormones also have been noted to induce squamous 
metaplasia, which plays a role in cervical neoplasia development when HPV is present in 
the tissue.81  
Moodley (2004) described the findings from eight studies conducted by the 
International Agency for Research on Cancer as well as a review on cervical neoplasia 
and the use of hormonal contraceptives.1 The author delineated four reasons for the 
conflicting and uncertain results on this issue. First, cervical neoplasia has an extremely 
long latent period which makes studying any associating factors extremely difficult. 
Second, over the course of their reproductive years, women are prescribed and use a 
variety of hormonal preparations.82 Thus, any association between a particular woman's 
cervical dysplasia or neoplasia and a type of hormonal contraception exposure may be 
 
16 
 
confounded by the use of several different preparations during the latent period between 
HPV infection and neoplasia development. Third, little research on the use of COCs has 
been conducted in women over the age of 35. Thus, knowledge is limited about the aging 
process and immune system function and the ability to avoid developing cervical 
dysplasia and neoplasia. Fourth, the author points to the wide variation in design methods 
and difference in data obtained in available studies.1 
 A study by the World Health Organization's International Agency for Research on 
Cancer (IARC)83 was included in the Moodley review and noted a fourfold increased risk 
of cervical neoplasia among women with persistent HPV infection and who had 
prolonged use of COCs. The IARC multicentric case control study reviewed eight studies 
of sexually active women from seven countries and effects were estimated as odds ratios 
with logistic regression models. The IARC group concluded that women taking COCs for 
5-9 years were approximately three times more likely to develop cervical neoplasia as 
compared to non-COC users. Women using COCs for greater than ten years had a 
fourfold greater risk, as compared to non-COC users.1 Women who had used oral 
contraceptives for less than five years did not demonstrate an increased risk of cervical 
neoplasia compared to women who had never used COCs (odds ratio 0.73; 95% CI 0.52-
1.03). The odds ratio for use of COCs was 2.82 (95% CI 1.46-5.42) for 5-9 years, and 
4.03 (2.09-8.02) for COC use of 10 or more years. The odds did not vary by time from 
either first or last use of COCs.83 The studies from which the pooled data were obtained 
were conducted in countries outside the U.S. including Thailand, the Philippines, 
Morocco, Brazil, Peru, Paraguay, Colombia, and Spain. The prevalence rates of the 
various types of high risk HPV differ from country to country,84and this may account for 
some of the variation in results between those studies conducted in and outside of the 
U.S.  
 
 Conflicting findings were noted in reviews by Green et al. (2003)85 and Smith et 
al.(2003).86 Smith et al. reviewed 28 studies to include 12,531 sexually active women 
with cervical neoplasia.86 The relative risks of cervical neoplasia increased in women 
who had used COCs compared with women who had never used COCs. Relative risk was 
calculated by the amount of years COC’s were used. For a usage period of less than five 
years, five to nine years, and 10 or more years, respectively, the summary relative risks 
were 1.1 (95% CI 1.1–1.2), 1.6 (1.4–1.7), and 2.2 (1.9–2.4) for all women; and 0.9 (0.7–
1.2), 1.3 (1.0–1.9), and 2.5 (1.6–3.9) for HPV positive women. The results were similar 
for the type and degree of neoplasia (whether in situ, invasive squamous cell or 
adenocarcinoma). The authors concluded that the limited available data suggested that the 
risk of cervical neoplasia may decrease after cessation of use of combined oral 
contraceptives. Limitations noted by the authors include the variation in study designs, 
method of analysis, and methods for measuring HPV.  
 
 Green et al. (2003) reviewed 19 studies with data on HPV status and COC use, 
with a total of 20, 509 subjects, to determine whether there was an association between 
the use of COC and HPV infection.85 The authors found no association between the use 
of COCs and the detection of HPV. Specifically, there was no association between 
duration of COC use and HPV positive status. A disparity noted among the studies was 
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that all studies measured HPV positive status but no distinction was made between recent 
and persistent infection. The persistence of HPV infection has been well established as a 
necessary component for the development of neoplasia.7 A point of difference between 
the studies in the Green, et al (2003)85 review and those in the Smith, et al.86 review was 
that there were varying numbers of women with normal cytology included. Some of the 
studies included women with normal cytology while others included women with a 
mixture of normal and abnormal cytology. This heterogeneity in subjects could explain 
the difference in findings between studies. Green et al (2003)85 also noted that there was 
no consistency between studies in relationship between HPV positivity and duration of 
COC use. Individual studies demonstrated increased, decreased or unchanged risk of 
HPV positivity by length of exposure to COC use. Some of the studies did not report 
length of progesterone exposure. Calculation of summary relative risks could not be done 
due to the lack of information on use duration as well as variability between study results.  
  
 A cohort study of more than 12,000 Argentinean and Brazilian women reported 
that length of use of hormonal contraception was not significantly related to an increased 
risk of high grade CIN.76 The variables that were noted to be associated with an increased 
risk of developing CIN (HR; 95% CI) were LSIL cytology at baseline (1.99; 1.42 -2.80) 
and high risk HPV infection (4.17; 1.74 - 9.96). Factors found to be unrelated to 
development of CIN were: 1) baseline HSIL cytology; 2) young age at coitarche; 3) age 
over 35 years; 4) ever having been pregnant; 5) number of births; 6) current smoking 
status; and 7) being single. This study cohort used various methods of hormonal 
contraception, including COCs, progesterone injection, patch, implant, vaginal ring, or 
progesterone IUD, as compared to the studies reviewed by Smith et al. (2003)86 and 
Green et al. (2003)85 where the subjects used only COCs. The mode of delivery of 
contraception (transdermal, versus oral versus local), and formulation (combined versus 
progesterone) could affect outcomes. The authors appropriately noted that making 
assumptions about hormonal contraception use and HPV is extremely complicated 
because infection with HPV is closely associated with sexual behavior patterns, which is 
in turn closely related to the choice of contraception a woman makes. Longatto-Filho et 
al. (2011) note that those studies in which a causal relationship is suggested should 
control for  sexual behavior as well as high risk HPV infection.76  
 
Multiple reasons have been cited for the difference in findings regarding COC use 
and cervical neoplasia risk. These reasons include variable and poor research design, use 
of homogenous populations, the implication that women who use COCs have 
characteristically different sexual patterns, as well as external factors which 
independently increase the risk for cervical neoplasia.1,76The argument has also been 
made that women who take COCs are more frequently screened for cervical neoplasia 
because they need to present periodically to their providers for a contraceptive 
prescription.87  
Two additional factors make it extremely challenging to study this issue. Women 
change contraceptive methods periodically throughout their reproductive years to prevent 
pregnancy, prevent sexually transmitted infections, or alter their menstrual cycle.88 This 
phenomenon makes it difficult to follow a cohort who use a singular method of 
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contraception for an extended period of years. Second, a study group with exactly the 
same internal and external risk factors for cervical neoplasia is difficult to obtain. 
Controlling for all of the factors that could confound results would be optimal, but not 
practical.84,87,89 
Cervical Neoplasia and Progesterone Use 
Progesterone alone has been implicated as a cofactor in the development of 
cervical neoplasia. Prolonged progesterone exposure was noted to enhance HPV 
colonization by way of increasing the HPV 16 E6/E7 oncogenic transcription.81 A 
corresponding greater  presence of HPV DNA has been noted among women with higher 
serum levels of progesterone.90 Progesterone thins the cervical and vaginal epithelium, 
which may lead to erosion and a secondary inflammation of the cervical tissue.91  
 A WHO study did not demonstrate an increased risk of invasive neoplasia for 
women using depot medroxyprogesterone acetate for extended periods of time.92 The use 
of depot medroxyprogesterone acetate was inversely associated with the incidence of 
CIN II-III or greater (OR adj, 0.4; 95% CI, 0.2-1.1) and CIN1 (OR adj, 0.1; 95% CI, 
0.01-0.6) among HPV positive women. Depot medroxyprogesterone acetate use was 
associated with high risk HPV (OR adj, 4.7; 95% CI, 1.4-15.8) among women who were 
histologically negative. The authors did conclude that longer-term depot 
medroxyprogesterone acetate use may weaken the colposcopic and histologic features of 
CIN because women using the injection were more likely to have cervical oncogenic 
HPV without evidence of CIN. The subjects in the study self-reported their hormonal 
contraception use.  The authors did not have documented information on whether the 
depot medroxyprogesterone acetate injections or COC use was continuous during the 
time period in which women reported having used the method. The subjects in this study 
who used COCs were using one of two very similar 35 microgram formulation COCs. 
Also, the average age of the subjects was younger than that of a typical gynecologic 
clinic population because this study was conducted at four Planned Parenthood sites. Of 
the 458 subjects, 406 (89%) were under 30 years of age.15 
 
  The relationship between the use of depot medroxyprogesterone acetate and 
cervical neoplasia was examined in a case-control study in Costa Rica. Subjects were 
women with either confirmed invasive squamous cell neoplasia (N = 149) or CIS 
(N = 415). Logistic regression models which included "ever having used" depot 
medroxyprogesterone acetate as well as age were used to uncover confounding effects of 
socioeconomic status, gravidity, use of Pap testing, age at coitarche, history of sexually 
transmitted infection, tobacco use, condom or oral contraceptive use, pelvic inflammatory 
history, marital status, douching, education or geographic region differences. Ever having 
used depot medroxyprogesterone acetate was associated with a risk of CIS of 1.1 (95% 
CI 0.6-1.8) and a risk of invasive neoplasia of 1.4 (95% CI 0.6-3.1). Neither duration of 
time exposure to progesterone nor length of time from either first or last use of the 
hormone was noted to have a significant pattern of CIS risk. The authors did note a small 
increased risk for those women whose first use of depot medroxyprogesterone acetate 
occurred after age 39 (risk of 2.0, 95% CI 0.8-5.5) when compared to women whose first 
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use was before age 30 (risk of 0.6, 95% CI 0.3-1.7). The authors noted that the slightly 
elevated risks detected may have been the result of either detection bias or chance. A 
limitation of this study was that very few women in the study had used the depot 
medroxyprogesterone for a period of time longer than two years. Also, all estimates for 
invasive neoplasia were based on only 10 cases who reported use of depot 
medroxyprogesterone acetate.93 
 
A New Zealand study on long term progesterone injection use noted that women 
with cervical dysplasia were more likely to have been using progesterone contraceptive 
injections prior to the development of the dysplasia compared to those who did not use 
progesterone injections. However, the researchers disclosed that the difference in results 
could be explained by the fact that women who used progesterone injections had very 
different sexual profiles than did the women who did not use progesterone injections. 
They tended to be younger at coitarche, have a greater number of lifetime sexual partners, 
and had a higher prevalence of cigarette smoking.94 
A case-control trial conducted in a population of Jamaican women (N = 338), 
noted use of hormonal contraception was associated both with dysplasia, (OR, 1.92 (CI 
1.11, 3.34; ρ = 0.02) and severity of the dysplasia (OR, 2.22 (CI 1.05, 4.66) ρ = 0.036). 
Hormonal contraception no longer retained significance when both alcohol consumption 
and parity were added to the model. The association with high risk cervical disease was 
retained when age and number of sexual partners were controlled. Depot 
medroxyprogesterone acetate use (with age and number of sexual partners as covariates) 
was also associated with dysplasia (OR, 2.43 (CI 1.39, 4.57), ρ = 0.006) and severity of 
disease (OR 2.51 (1.11, 5.64) ρ = 0.027). Depot medroxyprogesterone acetate use 
remained significant with parity and alcohol added to this model. Exposure to hormonal 
contraception for greater than four years resulted in higher risk for disease, as well as 
greater severity of disease.95 The sample was homogenous, all of Jamaican descent. 
Hormonal contraception also included various forms and delivery systems of hormonal 
contraception. The IUD group was not further delineated into copper or progesterone 
system. The sample was all women presenting to colposcopy clinic who already had 
received an abnormal cytology result. The subjects had existing documented cervical 
pathology, thus the effect of depot medroxyprogesterone acetate on women infected with 
HPV, who did not yet exhibit dysplasia, could not be measured.95  
Progesterone Effect on Cervical Cells 
The cellular effects of endogenous hormones are variable. Cellular changes that 
occur with menopause or pregnancy have been well documented in the literature. In 
contrast, there has been relatively little work done looking specifically at the cellular 
effect of progesterone only contraceptives, particularly the progesterone only intrauterine 
device (Mirena®). The existing literature is conflicting in nature.  
One of the first papers to describe a cellular effect of progesterone on cervical 
cells was that of Bonte et al.96 A shift in the cellular pattern was noted in 100 women who 
were administered depot medroxyprogesterone. Cervical cells of a woman who has gone 
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through menopause are normally predominantly atrophic or parabasal in nature. A 
predominantly parabasal cell pattern was noted in the cytologic samples of the Bonte et 
al. study group.96 This atrophic cellular appearance has subsequently been documented in 
women using depot medroxyprogesterone.17,97 Progesterone is thought to promote 
atrophy of the epithelial cells, as well as to decrease the cellular maturation pattern.5,33  
Cellular characteristics associated with the effect of progesterone exposure 
include curling or crowding of squamous cells, destruction of cells, and unusual 
morphology to cells (navicular or classically called "boat shaped"). Curling is described 
as a rounding or rolling of cervical cellular edges, while crowding has been defined as 
more than four cells in a closely spaced grouping. Navicular cells have a classic "boat" 
shape, as well as having curled cellular edges and centralized glycogen content.16 Kaptain 
et al. (2002) reviewed 157 cervical smears: 50 from depot medroxyprogesterone users, 55 
from women using COC, (Tri-Phasil®) and 51 from post-menopausal women.16 A 
definitive progesterone effect on the cells was noted. What was particularly of interest 
was that the anticipated progesterone effects of cellular crowding and curling were noted 
in both the combined progesterone and estrogen group and the depot 
medroxyprogesterone group (as compared to the post-menopausal group), but to a lesser 
extent in the depot medroxyprogesterone group than the COC group. Rates of cytolysis 
were similar among the COC and the depot medroxyprogesterone groups, though no 
cytolysis was noted in the post-menopausal group. The authors concluded that the 
progesterone effects were present more often in the COC group as compared to the depot 
medroxyprogesterone group. Both of the hormonal groups exhibited the progesterone 
cellular effects more so than the menopausal comparison group. The authors also noted 
that the duration of use of depot medroxyprogesterone did not have an effect on 
maturation of the squamous cells, which was thought to have been an issue with accurate 
interpretation. Part of the cellular evaluation in this study involved the use of a cellular 
maturational "perception scale," as devised by the authors, which differs from a 
maturational index (used by others). A cellular maturational perception scale may have 
different cellular categories to describe cellular changes, as compared to a maturational 
index scale. Maturation indexes are considered to be an objective method of classifying 
proportions of cells which are present in a given sample.98  
In contrast, Valente and colleagues used a maturational index value (MV) to 
examine the cytology samples of 29 women whose average time using depot 
medroxyprogesterone was 22.6 months, comparing them to a group of 25 non-
progesterone exposed women.17 The authors did note a significantly lower MV for the 
progesterone use group, as compared to the non-progesterone use group (38.45 versus 
64.60, p < 0.001).17 Of note, 16% of the cytologic specimens were graded as abnormal by 
the pathologist in the non-progesterone use group, whereas 21% were graded as abnormal 
in the progesterone exposed group. One LSIL result was confirmed as a low grade lesion 
in the progesterone use group, while three ASCUS result cytology specimens had a 
negative cytology result and/or histology at follow up. Two of the cytology samples in 
the progesterone user group were actually deemed as HSIL, but were noted to be negative 
in follow up cytology and/or biopsy. Two of the women in the non-progesterone use 
group who had HSIL results actually had a positive histology or cytologic test at follow 
 
21 
 
up. One woman with an ASCUS cytology result had a negative cytology test at follow 
up. The cellular changes associated with progesterone did create a degree of difficulty in 
correctly interpreting the cytology sample. Kaptain et al. (2001) noted that the cellular 
pattern on cytology samples from menopausal women, which was mostly parabasal in 
cell type, was distinctively different from the intermediate cellular pattern noted in 
cytology samples from both the COC group and the depot medroxyprogesterone.16 
Valente et al. (1998) argued that the cellular progesterone effects led to difficulty in 
accurate cytologic interpretation,17 but the findings of Kaptain et al. (2001) did not 
corroborate Valente et al's findings.  Kaptain's study compared the progesterone users to 
either women using one formulation of a COC (Triphasil®) to women who were 
menopausal. Valente's study compared depot medroxyprogesterone users to women who 
were non-progesterone exposed. The comparison groups were not the same in both 
studies, which could account for the difference in findings. Also, Valente and colleagues 
used a maturational index value to assess the samples in their study, which Kaptain et al. 
did not use. The use of a scale to assess cellular maturation could affect the classification 
of cellular changes in one study, not necessarily accounted for in a study where the same 
scale is not used.16,17  
Similar conflicting findings were noted by Knowles and Turbat-Herrera (1998)99 
and Zhu and Wilbur (1998).100 Knowles and Turbat-Herrera noted a greater number of 
cellular abnormalities in the cytologic samples of women using depot 
medroxyprogesterone (across the spectrum of squamous intraepithelial lesion), compared 
to a matched control group (57.1% versus 23.8%), while Zhu and Wilbur (1998) did not 
note any increased rate of ASCUS preceded SIL in women using progesterone only 
contraception, when compared to a control group of women with ASCUS.101,102 Zhu and 
Wilbur (1998)100 only used conventionally prepared glass slide cytologic sampling, as 
opposed to liquid cytology sampling. The recognition was made that nucleus/cytoplasmic 
ratios, which is a primary indicator of dysplasia, may undergo alteration when exposed to 
a liquid cytology medium, as compared to cells fixed on the traditional glass slide 
(without being first placed in a liquid medium). Knowles and Turbat-Herrera (1998)99 did 
not specify the cytology medium utilized in their study which could account for the 
difference in findings between these two studies. Another potential difference between 
these two study groups was that the Knowles and Turbat-Herrera study utilized subjects 
using depot medroxyprogesterone as the progesterone agent of exposure, whereas Zhu 
and Wilbur did not specify the progesterone agent that their subjects used other than to 
call it "progesterone therapy for contraception." There are multiple existing forms of 
"progesterone therapy for contraception,” and these could have altered the results.100 
Darwish et al.'s findings (2004)103 echo that of Kaptain et al. (2002)16 in one of 
the only studies to include an oral and implantable progesterone method study group. The 
study group was comprised of a subgroup of depot medroxyprogesterone users, a 
progesterone only oral pill group and an implantable progesterone implant group (no 
longer available as a contraceptive)., The progesterone exposure group had abnormal 
cervical cytology screening 19% of the time compared to a control group who were not 
exposed to any progesterone, but who did have a Cu-T 380A copper IUD in place for at 
least three years prior, who had 17.6% abnormal cytology screening. This finding was not 
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significant.6,92 The caveat of this study is that the comparison group consisted only of 
women with a copper IUD in situ. The copper IUD may affect cervical cytology such that 
there are cervical changes that, like the progesterone, are more likely to be misinterpreted 
by the pathologist as abnormal. There would be no difference in cytologic interpretation 
between progesterone users and copper IUD users if that were the case.  
An issue to be addressed is whether the false-positive cervical cytology rates 
differ for women using progesterone only contraceptive methods. Hoekstra et al. 
(2006)104 noted no difference in false-positive rates between hormonal contraception 
users and non-hormonal contraception users. The false- positive rates among non-
hormonal contraceptive users was 38% versus 33% among the hormonal contraception 
users. The literature varies on this issue; however, Drejet (1998)105 noted an increased 
epithelial cell abnormality rate in the cytologic samples of women using depot 
medroxyprogesterone, with a decreased confirmation of cervical dysplasia, suggesting 
that there may be a false positive phenomenon in the interpretation of samples from 
women using progesterone only methods.105 Conversely, Clark et al. (2011)36 did not find 
a higher rate of false positive cytology results comparing COC users to women using 
depot medroxyprogesterone.  
In summary, progesterone does have an effect on cervical cells. Progesterone 
induces atrophy and a pattern that is parabasal cell dominant, with the appearance of 
curling or crowding of squamous cells, destruction of cells, and navicular cell shape. The 
effect this altered pattern has on cytologic interpretation is less clear. There is evidence in 
the literature that these changes may induce difficulty in interpreting cytologic 
samples,105 though the literature is conflicting.  
Summary of the Chapter 
Accurate interpretation of cervical sampling is paramount to the correct diagnosis 
and treatment of cervical dysplasia and neoplasia. Factors which may affect accurate 
interpretation are important to investigate. The literature on adverse effects of 
progesterone on cervical cytology is minimal and conflicting as to whether changes in 
cell structure (cellular crowding, navicular shape change, atrophic changes) adversely 
affect the interpretation of the cytology sampling. The existing literature has also looked 
mainly at depot medroxyprogesterone. There is a gap in the knowledge regarding actual 
effect of progesterone on cytology, particularly in regards to the local effect of 
progesterone administered via exposure to the progesterone IUD (Mirena®). The existing 
evidence is unclear as to definitive progesterone effect.  
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CHAPTER 3. METHODOLOGY 
Overview 
The purpose of this study was to examine the accuracy of cervical cytologic 
findings in women who were using either one of two forms of progesterone only 
contraception, depot medroxyprogesterone acetate injection or the progesterone IUD, as 
compared to women who either used a non-hormonal form of contraception, or no 
contraception at all. Accuracy, for the purposes of this study, was defined as the 
association between cytology interpretation and histology interpretation. A secondary 
purpose of the study was to investigate whether the length of time of progesterone 
exposure had an effect on the association between cytologic and histologic findings. In 
this chapter, the methodology is outlined to include research design, sampling, method of 
data retrieval and procedure, measurements, and analysis.  
Research Design 
 A non-experimental retrospective design was used for this descriptive study. The 
database used for the study was the Synthetic Derivative (SD) electronic medical record 
base from Vanderbilt University Medical Center (VUMC), which is a de-identified copy 
of the main hospital medical record databases created for research purposes. 
Sample 
Institutional Review Board approval was obtained at both Vanderbilt University 
and the University of Tennessee Health Science Center. The SD database is a research 
database developed at Vanderbilt University to facilitate studies using de-identified 
clinical data. Consent for an individual’s medical record inclusion into the SD is obtained 
when patients are seen at any of the Vanderbilt associated clinics and facilities. The 
database contains a total of 1.7 million patient records, with highly detailed longitudinal 
clinical data for approximately one million subjects, with an average clinical record size 
of 106,727 bytes and an average of 13 distinct International Classification of Disease, 9th 
revision codes (ICD-9) per record. The database incorporates data from multiple sources 
and includes diagnostic (ICD-9) and current procedural terminology (CPT) codes, basic 
demographics (age, gender, race), text from clinical care including discharge summaries, 
nursing notes, progress notes, history and physical, problem lists and multi-disciplinary 
assessments, laboratory values, electrocardiogram (ECG) diagnoses, clinical text and 
electronically derived trace values, and inpatient medication orders. The de-identification 
of the records is achieved through the application of a commercial electronic program, 
which is applied and assessed for acceptable effectiveness in scrubbing identifiers. All 
clinical data are updated regularly to include the addition of both new patients to the 
database, as well as appending of existing records. Thus, the resource is suitable for 
mining information relative to disease progression over time.  
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The SD is stored on a secure server housed in the Vanderbilt Data Center and is 
fully compliant with the administrative, physical, and technical provisions of the Health 
Insurance Portability and Accountability Act (HIPAA) Security and Privacy Rules. The 
SD database is hosted on a Sun Solaris Server and running on Oracle 10g Software. The 
SD is mirrored by fully redundant server architecture in the event of a production server 
failure. Simple queries to the Synthetic Derivative (the number of records which meet 
certain criteria) are available by a user interface hosted on the VUMC intranet. For this 
study, custom datasets were created through a formal request submitted to the BioVU 
office at Vanderbilt University. There was no threat to confidentiality, as all participant 
records had been de-identified prior to inclusion in the synthetic derivative database, 
which was in compliance with the HIPAA guidelines for electronic data. There were no 
other potential risks identified. 
 Inclusion criteria for the study included women less than 60 years of age with an 
abnormal cervical cytologic report or abnormal histology report at colposcopy, who were: 
• Using the levonorgestrel intrauterine device (Mirena®) for at least six completed 
months prior to abnormal cytology/histology result, or; 
• Using the depot medroxyprogesterone injection 150 mg dose (Depo Provera®) 
for at least six completed months prior to abnormal cytology/histology result, or; 
• Using non-hormonal contraception for at least six completed months prior to 
abnormal cytology/histology result, or; 
• Using no contraception for at least six completed months prior to abnormal 
cytology/histology result. 
 Exclusion criteria for the study were: 
• Women who used combined oral contraception (containing both estrogen and 
progesterone). 
• Current pregnant or post-menopausal status. 
• Women who met the inclusion criteria, but did not have either a cervical biopsy or 
an endocervical curettage done at colposcopy. 
• Women who were not using any contraception, but who had used a progesterone 
containing contraceptive up to, but not including the six months prior to, the 
abnormal cytology result were excluded. 
Levonorgestrel IUD is a five year product, so records of individuals using 
Mirena® were searched for the 6 years prior to abnormal cytology results. Going back at 
least six years from the time of the colposcopy procedure would capture the insertion 
procedures of the IUD.  This was important to be able to capture subjects who had the 
IUD in situ, whose records did not make mention of it after the initial insertion. A period 
of five years prior to abnormal cytology was chosen to go back into the progesterone 
injection user's records to be able to capture those records wherein a woman may have 
been using the medication at the time of colposcopy, but inadvertently did not have 
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mention of it in her record. Of note, women with ASCUS cytology results, without 
accompanying HPV results, were retained as subjects. Women who had an ASCUS HPV 
negative cytology result were referred to colposcopy prior to the release of the 2006 
abnormal cytology guidelines and the use of reflex HPV testing. Repeat cytology in one 
year is the current recommendation with an ASCUS HPV negative result, rather than 
colposcopy. Practitioners recommend colposcopy if ASCUS persists beyond one year.36 
Cytology results of ASCUS with a negative accompanying HPV remained in the 
inclusion criteria for abnormal cytology because it is classified as an abnormal result.  
The first two inclusion criteria entered to search the database were females less 
than 60 years of age with one or more of the following CPT codes (for varying types of 
colposcopy): 57452, 57454, 57455, 57456, 57460, or 57461. Records were excluded that 
mentioned any of the excluded COCs.  Also excluded were subjects who were currently 
pregnant, or pregnant within the preceding 9 months or those with ICD-9 codes of V22 or 
V23 (pregnancy) within the nine months prior to the colposcopy. The three study sets 
were constructed from this initial group of records.  
Group 1 included all records which met the criteria mentioned previously, and 
excluded every record in set 2 or 3. Group 2 included everything that met criteria for set 
1, as well as having to have had a mention of Mirena® OR Levonorgestrel or CPT J7302 
within six years prior to the colposcopy CPT dates. Group 3 included all of those records 
that met criteria for set 1, with the added requisite that there had to have been a mention 
of one or more of the following medications (Depo Provera® or Depot Provera® OR 
depot medroxyprogesterone) or CPT codes for them (J1055), within five years prior to 
the colposcopy CPT date. Dataset 1 contained 6,515 records, dataset 2 contained 142 
records, and dataset 3 contained 470 records. A final group of all progesterone users was 
formed for the purposes of analysis which contained the records of those in groups 2  
and 3.  
Setting and Recruitment 
A large academic medical center located in Nashville, Tennessee was the 
origination site for the SD. Recruitment of subjects was accomplished via the submission 
of specific search data into the database as described in the sampling section. The study 
received exempt review status from both Institutional Review Boards.  
Procedures 
The SD was accessed via secure login and password. The records had been loaded 
into the database by the BioVu office after they were formed. The anatomical pathology 
portion of each record was examined to ensure that a cervical biopsy had been done 
following the abnormal cytology result. The record was omitted from use if neither a 
cervical histology sample, nor an endocervical curettage had been collected. 
Demographic data, cytology and corresponding histology results were recorded in a 
Microsoft Excel® formatted codebook after the record was verified for the presence of a 
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histology sample. Every record in both the IUD group and the progesterone injection 
group was examined. Records in the non-hormonal-no contraception group were 
reviewed and added until the sample size was comparable to the progesterone injection 
group  
Data cleaning occurred prior to analysis. Records were excluded for the following 
reasons: 94 had no histologic specimen collected after the abnormal cytology result; 40 
had no abnormal cytology result preceding colposcopy; 30 progesterone injection users 
could not be verified for length of use of the injection; 21 did not have contraceptive type 
recorded; eight were using COC at the time of the abnormal cytology result; six were 
pregnant at the time of the cytologic screening; six records did not indicate how long the 
progesterone IUD had been in situ: four used the combined contraceptive patch, one did  
not have the IUD in at least six months; one had colposcopy done only as result of 
abnormal endometrial biopsy and not abnormal cytology result; one had no cytology 
result in the chart; one had no histology result in the chart, one cytology screening was 
done post hysterectomy, and whether ovaries were removed could not be verified; and 
one cytology screening was done after hysterectomy with no subsequent histology 
collection. This resulted in the following sample sizes: group one equaled 72, group two 
equaled 35 and group three equaled 73. The final group, which combined groups two and 
three equaled 108. All data were exported into Statistical Package for the Social Sciences, 
Statistics Data Editor (SPSS) version 19.106 
Data Analysis 
Descriptive data included age, race, marital status, gravida and parity, smoking 
status, years of tobacco use and amount used, contraceptive use and type used, abnormal 
cytologic sample result type and resultant histology typing. Time lapse between the 
abnormal cytologic screen report and the subsequent colposcopy was recorded, as well as 
the amount of time the participant had been using the progesterone product, if applicable. 
Chi square analysis was performed to evaluate variations in the proportions of women in 
each group (the progesterone IUD group, the progesterone injection group and the non-
progesterone use group).  
Coding for Analysis 
Cytology results were collapsed and recoded as an ordinal variable (low, high). 
Histology results were also collapsed and recoded as an ordinal variable (neg, low, high). 
Collapsing results in this manner is consistent with Bethesda System 2001 for combining 
moderate and severe dysplasia and is historically, and currently, how these results are 
collapsed for purpose of research. If groups had not been collapsed for the purpose of 
analysis, the cells for each individual cytology and histology combination would have 
been too small for analysis. Therefore, all of the following cytology results were 
collapsed into group 1 (low grade): ASCUS without HPV result; ASCUS, HPV positive; 
ASCUS, HPV negative; and LSIL. All of the following were collapsed into group 2 (high 
grade): HSIL, AGC, ASCUS-H, and LSIL-H. Histology and endocervical curettage 
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results were collapsed into three categories. Histology results that were negative were 
coded as group 0 (Table 3-1). Group 1 (low grade) contained: cervicitis and CIN I 
histology results. All of the following were collapsed into group 2 (high grade): CIN II; 
CIN III; CIS; invasive neoplasia and glandular adenocarcinoma.  
Research questions two and three dealt with the relationship between cytology 
and histology. Chi square analysis was undertaken to address these questions. The first 
step involved analyzing the association between cytology and histology by progesterone 
exposure per group, and comparing no progesterone exposure to those who had any 
progesterone exposure. The second step looked at agreement by either agree/disagree by 
type of progesterone exposure first, and then by either no progesterone exposure or any 
progesterone exposure. The latter half of that analysis examined the cytology/histology 
relationship using the terms agree, false negative or false positive, according to type of 
progesterone exposure, and then any exposure versus no exposure. 
A new outcome variable was then created to describe the relationship between 
cytology and histology in the four groups of subjects in order to analyze agreement 
between results of cytology and histology by progesterone exposure. This particular 
portion of the analysis was something that has not been seen previously, and is unique to 
this study. Creation of a new defining outcome variable allowed for a greater degree of 
discrimination in determining the relationship between cytology and histology. The first 
level agreement variable was defined simply as the discrete "agree," (yes or no) and was 
applied to the cytology/histology relationship in terms of whether the particular 
relationship was consistent with what would be expected, or not. The second level of 
agreement consisted of the discrete variables of "agree,” "false negative," or "false 
positive," for every combination of cytology and histology result (Table 3-2). An "agree" 
by definition meant that the histology result was consistent with what would be expected 
from the preceding cytology result. A "false positive" existed if the cytology result was at 
a greater level of abnormality than the corresponding histology result. A "false negative" 
existed when the cytology result was a lesser degree of abnormal than the subsequent 
histology result. 
 The new defining outcome variable added greater depth of understanding of the 
relationship between cytology and histology. The nuances that occur within the low and 
high grade cytology/histology pairings would not be accounted for if analysis had ceased 
with the collapsing of cytology and histology into simply low grade and high grade 
groupings. The assumption would be, for example, that a cytology result in the low grade 
category, paired with a subsequent histology result also in the low grade category would 
represent an agree relationship between the cytology and histology. However, there are 
three cytology/histology combinations within the low grade pairings which actually 
represent a false positive, rather than an agreement situation. There are also three 
cytology/histology combinations that represent false negative in the high grade cytology 
and histology combinations.  
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Table 3-1. Categorization of cytology and histology results into collapsed 
categories 
Cytology results 
collapsed into low 
grade category 
Cytology results 
collapsed into high 
grade category 
Histology results 
collapsed into low 
grade category 
Histology results 
collapsed into high 
grade category 
ASCUS without 
HPV  
ASCUS HPV 
positive 
ASCUS HPV 
negative 
LSIL 
HSIL 
AGC 
ASCUS-H 
LSIL-H 
Cervicitis 
CIN I 
CIN II 
CIN III 
CIS 
Invasive neoplasia 
Glandular 
Adenocarcinoma 
 
Abbreviations: ASCUS without HPV, atypical squamous cells of undetermined 
significance with no human Papilloma virus test result; ASCUS HPV positive, atypical 
squamous cells of undetermined significance with a positive human Papilloma virus test 
result; ASCUS HPV negative, atypical squamous cells of undetermined significance with 
a negative human Papilloma virus test result; LSIL, low grade squamous intraepithelial 
lesion; HSIL, high grade squamous intraepithelial lesion; AGC, atypical glandular cells; 
ASCUS-H, atypical squamous cells of undetermined significance, cannot rule out high 
grade; LSIL-H, low grade squamous intraepithelial lesion, cannot rule out high grade; 
CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ. 
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Table 3-2. Definition of agreement between cytology and histology 
Pap biopsy/ECC ASCUS 
no HPV 
ASCUS 
HPV neg 
ASCUS 
HPV pos 
LSIL HSIL AGC ASCUS-H LSIL-H 
Negative Agree Agree False 
positive 
False 
positive 
False 
positive 
False 
positive 
False 
positive 
False 
positive 
Cervicitis Agree Agree Agree False 
positive 
False 
positive 
False 
positive 
False 
positive 
False 
positive 
CIN I Agree Agree Agree Agree False 
positive 
False 
positive 
Agree Agree 
CIN II False 
negative 
False 
negative 
False 
negative 
False 
negative 
Agree Agree Agree Agree 
CIN III False 
negative 
False 
negative 
False 
negative 
False 
negative 
Agree Agree Agree Agree 
CIS False 
negative 
False 
negative 
False 
negative 
False 
negative 
Agree Agree Agree Agree 
Invasive CA False 
negative 
False 
negative 
False 
negative 
False 
negative 
Agree Agree Agree Agree 
Adenocarcinoma False 
negative 
False 
negative 
False 
negative 
False 
negative 
False 
negative 
Agree False 
negative 
False 
negative 
 
Abbreviations: ECC, endocervical curetage; ASCUS no HPV, atypical squamous cells of undetermined significance 
with no human Papilloma virus test result; ASCUS HPV pos, atypical squamous cells of undetermined significance 
with a positive human Papilloma virus test result; ASCUS HPV neg, atypical squamous cells of undetermined 
significance with a negative human Papilloma virus test result; LSIL, low grade squamous intraepithelial lesion;  
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Table 3-2. (Continued) 
HSIL, high grade squamous intraepithelial lesion; AGC, atypical glandular cells; ASCUS-H, atypical squamous cells of 
undetermined significance, cannot rule out high grade; LSIL-H, low grade squamous intraepithelial lesion, cannot rule 
out high grade; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ. 
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Analysis for Individual Questions 
Statistical methods used in this study included measures of central tendency 
including means, ranges and standard deviations as well as Chi square analysis, and 
logistic regression. Descriptive analysis was run on each of the three groups 
independently, and then on the combined group of the IUD and injection group to address 
research question one. The continuous variable data collected included age, years 
smoked, amount smoked, gravid/parity, and length of time between Pap and subsequent 
biopsy. Categorical variable data collected included race, marital status, smoking status, 
history of prior abnormal cytology result, and history of prior cervical treatment.  
Chi square analysis was run on the newly formed collapsed groups to address 
research question two. This was performed to evaluate the relationship between cytology 
findings and histology findings across the entire sample. This analysis was done to 
determine the relationship between cytology and histology results. Regrouping according 
to progesterone exposure was also necessary for the two Chi square analyses undertaken 
to analyze cytology/histology results by progesterone exposure. In the first Chi square 
analysis, subjects were either in the non-hormonal or no contraception group, the 
progesterone IUD group, or the progesterone injection group. In the second Chi square 
analysis undertaken to look at progesterone exposure, the subjects in either of the two 
progesterone groups (the IUD or the progesterone injection group) were collapsed into 
the progesterone group, and all others not exposed to progesterone were included in the 
no progesterone group.  
 Four Chi square analyses were run to answer research question three. Results 
were then compared across the groups to determine if there was a difference in the 
relationship between cytology and histology in groups of women with abnormal cytology 
test results. Two logistic regressions were undertaken in which the variables of time on 
progesterone, age, group (whether IUD or injection), and group by time on progesterone 
were analyzed for interaction to address research question four. Age was adjusted for in 
this analysis because it is realistic to supposed that the older a woman is, the greater the 
amount of time she could have theoretically been exposed to progesterone. The first 
regression model analyzed progesterone in the context of agree (y/n), and the second in 
the context of false positive (y/n).   
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CHAPTER 4. RESULTS 
The purpose of this study was to examine the accuracy of cervical cytologic 
findings in women who were using either one of two forms of progesterone only 
contraception, as compared to women who used either a non-hormonal form of 
contraception or no contraception at all. Accuracy, for the purposes of this study, was 
defined as the association between cytology interpretation and histology interpretation. A 
secondary purpose of the study was to investigate whether the length of time of 
progesterone exposure had an effect on the association between cytologic and histologic 
findings.  
Research Question 1: What Are the Characteristics (Demographic,  
Gynecologic and Smoking History) of Four Groups of Women Who Have  
Abnormal Cytologic Test Results? 
 
Characteristics of the sample 
 Table 4-1 reports the characteristics of the sample for this study.  Each of the 
three groups (no progesterone exposure, IUD users, and injection users) is included as 
well as a fourth group which was constructed by combining subjects with any 
progesterone exposure (the IUD and injection groups). There were 180 subjects who 
were between the ages of 14 and 79 years with a mean age of 27.5 years (SD ± 7.2). Most 
subjects were either black (46.7%) or white (41.7%) and the remainder were Asian 
(1.1%), Hispanic (1.1%), other (0.6%) or did not have a recorded race (8.9%).  Forty-
eight (26.7%) of subjects were married with the  largest percentage of married women in 
the IUD group (45.7%) and the lowest percentage  (15.1%) in the progesterone injection 
group Approximately one third of the subjects (30.6%) smoked but this varied from a low 
of 22.2% for non-hormone/no contraception subjects to a high of 41.1% for injection 
progesterone uses.  As noted in Table 4-1 there are similarities in the length of time 
smoking and amount smoked for the different groups. 
The largest number of nulligravid women was in the progesterone injection group 
(16.4%) and the smallest number (11.4%) in the IUD group. Elapsed time between 
collection of Pap and subsequent colposcopy (in weeks) was greatest in the progesterone 
injection group (11.8 ± 10.9), and least in the non-hormonal/no contraception group 
(6.9 ± 7.6). Nearly half of the sample had a prior abnormal cytology result (45.6%), and 
12.8% had received prior cervical treatment for dysplasia. Prior treatment was either cold 
knife cone, cryotherapy or loop electrosurgery excision procedure.  
Frequency of cytologic and histologic abnormalities 
 
 Table 4-2 reports the cytologic and histologic results by group. The most 
common cytology result among all subjects was LSIL (42.8%) while the least common 
 
33 
 
Table 4-1. Sample characteristics 
Characteristics Non-hormonal or 
no contraception 
(n = 72) 
Progesterone IUD 
group 
(n = 35) 
Progesterone 
injection group 
(n = 73) 
Combined IUD 
and injection 
group (n = 108) 
All subjects in all 
groups 
(n = 180) 
Age n ± SD 28.1 ± 7.8 
range 16-49 
28.5 ± 5.8 
range 20-43 
26.3 ± 7.1 
range 14-43 
27.0 ± 6.8 
range 14-43 
27.5 ± 7.2 
range 14-49 
Race n (%) 
White 
Black 
AI 
Asian 
Hawaiian/PI 
Hispanic 
Other 
Unknown 
 
35 (48.6) 
27 (37.5) 
0 
0 
0 
2 (2.8) 
1 (1.4) 
7 (9.7) 
 
19 (54.3) 
10 (28.6) 
0 
0 
0 
0 
0 
6 (17.1) 
 
21 (28.8) 
47 (64.4) 
0 
2 (2.7) 
0 
0 
0 
3 (4.1) 
 
40 (37.0) 
57 (52.8) 
0 
2 (1.9) 
0 
0 
0 
9 (8.3) 
 
75 (41.7) 
84 (46.7) 
0 
2 (1.1) 
0 
2 (1.1) 
1 (0.6) 
16 (8.9) 
Marital status  
n (%) 
Unmarried 
Married 
Divorced 
Unknown 
 
 
39 (54.2) 
21 (29.2) 
2 (2.8) 
10 (13.9) 
 
 
15 (42.9) 
16 (45.7) 
3 (8.6) 
1 (2.9) 
 
 
42 (57.5) 
11 (15.1) 
7 (9.6) 
13 (17.8) 
 
 
57 (52.8) 
27 (25.0) 
10 (9.3) 
14 (13.0) 
 
 
96 (53.3) 
48 (26.7) 
12 (6.7) 
24 (13.3) 
Smoker n (%) 
Non-smoker 
Smoker 
Former  
Unknown 
 
38 (52.8) 
16 (22.2) 
6 (8.3) 
12 (16.7) 
 
25 (71.4) 
9 (25.7) 
0 
1 (2.9) 
 
33 (45.2) 
30 (41.1) 
0 
10 (13.7) 
 
58 (53.7) 
39 (36.1) 
0 
11 (10.2) 
 
96 (53.3) 
55 (30.6) 
6 (3.3) 
23 (12.8) 
Years smoked  
n ± SD 
6.3 ± 6.6  
range 1-18 
10.3 ± 7.5  
range 2-18 
7.7 ± 7.0  
range 0-20 
8.7 ± 6.9  
range 0-20 
7.8 ± 6.7  
range 0-20 
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Table 4-1. (Continued) 
Characteristics Non-hormonal or 
no contraception 
(n = 72) 
Progesterone IUD 
group 
(n = 35) 
Progesterone 
injection group 
(n = 73) 
Combined IUD 
and injection 
group (n = 108) 
All subjects in all 
groups 
(n = 180)  
Amount 
smoked 
n ± SD  
 
12.9 ± 9.0  
range 2-40 
 
13.0 ± 5.3  
range 7-20 
 
17.2 ± 12.3  
range 2-60 
 
16.1 ± 11.0  
range 2-60 
 
15.0 ± 10.3  
range 2-60 
Gravida n (%) 
Nulligravid 
One 
Two 
Three 
Four 
Five 
Six 
 
10 (13.9) 
21 (29.2) 
21 (29.2) 
12 (16.7) 
4 (5.6) 
2 (2.8) 
1 (1.4) 
 
4 (11.4) 
17 (48.6) 
5 (14.3) 
4 (11.4) 
4 (11.4) 
0 
0 
 
12 (16.4) 
13 (17.8) 
28(38.4) 
9 (12.3) 
6 (8.2) 
2 (2.7) 
0 
 
16 (14.8) 
30 (27.8) 
33 (30.6) 
13 (12) 
10 (9.3) 
2 (1.9) 
0 
 
26 (14.4) 
51 (28.3) 
54 (30) 
25 (13.9) 
14 (7.8) 
4 (2.2) 
1 (0.6) 
Parity n (%) 
Nulliparous 
One 
Two 
Three 
Four 
Five  
 
18 (25) 
23 (31.9) 
22 (30.6) 
6 (8.3) 
1 (1.4) 
1 (1.4) 
 
4 (11.4) 
17 (48.6) 
9 (14.3) 
4 (11.4) 
0 
0 
 
17 (23.3) 
22 (30.1) 
21 (28.8) 
8 (11.0) 
0 
2 (2.7) 
 
21 (19.4) 
39 (36.1) 
30 (27.8) 
12 (11.1) 
0 
2 (1.9) 
 
39 (21.7) 
62. (34.4) 
52 (28.9) 
18 (10) 
1 (0.6) 
3 (1.7) 
Time between  
cytology and 
colposcopy 
weeks ± SD 
 
 
6.9 ± 7.6 
range 0-40 
 
 
7.4 ± 7.3 
range 0-28 
 
 
11.8 ± 10.9 
range 0-44 
 
 
10.4 ± 10.0 
range 0-44 
 
 
9.0 ± 9.3 
range 0-44 
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Table 4-1. (Continued) 
Characteristics Non-hormonal or 
no contraception 
(n = 72) 
Progesterone IUD 
group 
(n = 35) 
Progesterone 
injection group 
(n = 73) 
Combined IUD 
and injection 
group (n = 108) 
All subjects in all 
groups 
(n = 180) 
History of prior 
abnormal 
cytology n (%) 
No 
Yes 
Unknown 
 
 
 
45 (62.5) 
25 (34.7) 
2 (2.8) 
 
 
 
19 (54.3) 
15 (42.9) 
1 (2.9) 
 
 
 
31 (42.5) 
42 (57.5) 
0 
 
 
 
50 (46.3) 
57 (52.8) 
1 (0.9) 
 
 
 
95 (52.8) 
82 (45.6) 
3 (1.7) 
History of 
cervical  
treatment  
n (%) 
No 
Yes 
Unknown 
 
 
 
 
63 (87.5) 
7 (9.7) 
2 (2.8) 
 
 
 
 
30 (85.7) 
4 (11.4) 
1 (2.9) 
 
 
 
 
60 (82.2) 
12 (16.4) 
1 (1.4) 
 
 
 
 
90 (83.3) 
16 (14.8) 
1 (1.9) 
 
 
 
 
153 (85) 
23 (12.8) 
4 (2.2) 
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Table 4-2. Cytology result, cervical histology result, and endocervical curettage result by progesterone 
exposure (n = 180) 
Results Non-hormonal or 
no contraception 
(n = 72) 
Progesterone 
IUD 
(n = 35) 
Progesterone 
injection 
(n = 73) 
Total all 
subjects 
(n = 180) 
Progesterone 
exposure by either 
IUD or injection 
(n = 108) 
Cytology result  
n (%) 
ASCUS no HPV  
ASCUS HPV -   
ASCUS HPV +  
ASCUS-H 
 LSIL   
 LSIL-H 
 HSIL  
 AGC  
 
 
0 
0 
17  
3 
 30  
1  
17  
4  
 
 
1  
0 
8  
3  
14  
1  
8  
0 
 
 
5  
1  
8  
5  
33  
1  
17 
3  
 
 
6  
1  
33  
11  
77  
3  
42  
7  
 
 
6  
1  
16  
8  
47  
2  
25  
3  
Histology result  
n (%) 
Neg 
Cervicitis 
CIN I 
CIN II  
CIN III  
CIS  
Invasive CA 
Adenocarcinoma 
Not done  
 
 
12  
10  
21  
8  
6  
0 
0 
0 
15  
 
 
9 
6  
10  
6  
0 
0 
0 
0 
4   
 
 
10  
14  
20  
9  
6  
0 
0 
0 
14  
 
 
31  
30 
51  
23  
12  
0 
0 
0 
33  
 
 
19  
20  
30  
15  
6  
0 
0 
0 
18  
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Table 4-2. (Continued) 
 
Abbreviations: ASCUS no HPV, atypical squamous cells of undetermined significance with no human Papilloma 
virus test result; ASCUS HPV +, atypical squamous cells of undetermined significance with a positive human 
Papilloma virus test result; ASCUS HPV -, atypical squamous cells of undetermined significance with a negative 
human Papilloma virus test result; LSIL, low grade squamous intraepithelial lesion; HSIL, high grade squamous 
intraepithelial lesion; AGC, atypical glandular cells; ASCUS-H, atypical squamous cells of undetermined significance, 
cannot rule out high grade; LSIL-H, low grade squamous intraepithelial lesion, cannot rule out high grade; CIN, 
cervical intraepithelial neoplasia; CIS, carcinoma in situ. 
Results Non-hormonal or 
no contraception 
(n = 72) 
Progesterone 
IUD 
(n = 35) 
Progesterone 
injection 
(n = 73) 
Total all 
subjects 
(n = 180) 
Progesterone 
exposure by either 
IUD or injection 
(n = 108) 
Endocervical 
curettage result 
n (%) 
Neg  
Cervicitis 
CIN I 
CIN II 
CIN III 
CIS 
Invasive CA 
Adenocarcinoma 
Not done 
 
 
 
34 
0 
0 
1 
0 
0 
0 
0 
37 
 
 
 
19  
0 
0 
0 
0 
0 
0 
0 
16 
 
 
 
39  
0 
0 
1 
1 
0 
0 
0 
32  
 
 
 
92 
 0 
0 
2 
1  
0 
0 
0 
85 
 
 
 
58 
0 
0 
1  
1  
0 
0 
0 
48 
Time on 
progesterone 
months ± SD 
NA 20.4 ± 13.6 
range 
6-60 
27.9 ± 22.6 
range 
5-168 
NA 25.5 ± 20.4 
range 5-168 
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was ASCUS high risk HPV negative (0.6%).  Table 4-2 shows the differences within 
group for the various results. 
 
Research Question 2: What is the Relationship between Cytology and Histology 
 in Four Groups of Women with Abnormal Cytology Results? 
Answering Research Question 2 required that certain components of the data had 
to be collapsed.  The cytology results were collapsed into the low grade group (ASCUS 
no HPV result, ASCUS HPV positive, ASCUS HPV negative, and LSIL) and a high 
grade group (HSIL, AGC, ASCUS-H and LSIL-H). Similarly, the histology results were 
collapsed into three groups of negative, low grade (Cervicitis, CIN I) and high grade 
(CIN II, CIN III, CIS, Invasive neoplasia and Glandular Adenocarcinoma). Table 4-3 
shows the cross tabulation of these groups.  These groups were then analyzed by the use 
of Somers' D, which is used to analyze association between two ordinal variables 
(cytology and histology). A significant relationship (p =  0.008), was found between 
results of cytology and histology samples. 
 
The results were then analyzed by evaluating various levels of progesterone 
exposure for the subjects.  Tables 4-4 through 4-7 show the results of these analyses.  
Again, the data were collapsed as described in Table 4-3. Table 4-4 shows the cross 
tabulation of subjects with no progesterone exposure. These groups were then analyzed 
by the use of Somers' D. A significant relationship (p =  0.019) was found between 
results of cytology and histology samples for subjects with no progesterone exposure. 
 
Table 4-5 notes results of the analysis between cytology and histology in the IUD 
group. Again, the data were collapsed as described above in Table 4-3. This group was 
then analyzed by the use of Somers' D. A significant relationship (p =  0.019) was found 
between results of cytology and histology samples for subjects using the progesterone 
IUD. 
 
Table 4-6 notes results of the analysis between cytology and histology in the 
injection group. Again, the data were collapsed as described above in Table 4-3. This 
group was then analyzed by the use of Somers' D. No significance was found in the 
relationship (p =  0.790) between results of cytology and histology samples for subjects 
using the progesterone injection. 
 
Table 4-7 notes results of the analysis between cytology and histology for 
subjects with any progesterone exposure. Again, the data were collapsed as described 
above in Table 4-3. This group was then analyzed by the use of Somers' D. No 
significance was found in the relationship (p =  0.131) between results of cytology and 
histology samples for subjects with any progesterone exposure. 
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Table 4-3. Crosstabulation of collapsed cytology and histology results for all 
cases (n = 180) 
Histology result  Cytology result  
  Low grade* 
(n = 117) 
n (%) 
High grade** 
(n = 63) 
n (%) 
Total 
(n = 180) 
 
 
Negative  43 (36.8) 20 (31.7) 63  
Low grade***  63 (53.8) 18 (28.6) 81  
High grade****  11 (9.4) 25 (39.7) 36  
Total  117 63 180  
% of total  65 35   
 
Notes: Somers’ D p = 0.008.  
*Low grade cytology includes ASCUS no HPV result, ASCUS HPV positive, ASCUS 
HPV negative, and LSIL. 
**High grade cytology includes HSIL, AGC, ASCUS-H, and LSIL-H. 
*** Low grade histology includes Cervicitis, CIN I. 
**** High grade histology includes CIN II, CIN III, CIS, invasive neoplasia, 
adenocarcinoma. 
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Table 4-4. Crosstabulation of collapsed cytology and histology results for no 
progesterone exposure (n = 72) 
Histology result  Cytology result  
  Low grade* 
(n = 47) 
n (%) 
High grade** 
(n = 25) 
n (%) 
Total 
(n = 72) 
n (%) 
 
Negative  19 (40.4) 7 (28.0) 26 (36.1)  
Low grade***  24 (51.1) 7 (28.0) 31 (43.1)  
High grade****  4 (8.5) 11 (44.0) 15 (20.8)  
Total  47 25 72  
% of total  65.3 34.7 100.0  
 
Notes: Somers’ D p = 0.019.  
*Low grade cytology includes ASCUS no HPV result, ASCUS HPV positive, ASCUS 
HPV negative, and LSIL. 
**High grade cytology includes HSIL, AGC, ASCUS-H, and LSIL-H. 
*** Low grade histology includes Cervicitis, CIN I. 
****High grade histology includes CIN II, CIN III, CIS, invasive neoplasia, 
adenocarcinoma. 
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Table 4-5. Crosstabulation of collapsed cytology and histology results for 
progesterone IUD (n = 35) 
Histology result  Cytology result  
  Low grade* 
(n = 23) 
n (%) 
High grade** 
(n = 12) 
n (%) 
Total 
(n = 35) 
n (%) 
 
Negative  10 (43.5) 3 (25.0) 13 (37.1)  
Low grade***  13 (56.5) 3 (25.0) 16 (45.7)  
High grade****  0 (0.0) 6 (50.0) 6 (17.1)  
Total   23 12 35  
% of total   65.0 35.0 100.0  
 
Notes: Somers’ D p = 0.019. 
 
*Low grade cytology includes ASCUS no HPV result, ASCUS HPV positive, ASCUS 
HPV negative, and LSIL. 
**High grade cytology includes HSIL, AGC, ASCUS-H, and LSIL-H. 
*** Low grade histology includes Cervicitis, CIN I. 
****High grade histology includes CIN II, CIN III, CIS, invasive neoplasia, 
adenocarcinoma. 
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Table 4-6. Crosstabulation of collapsed and histology results for progesterone 
injection (n = 73) 
Histology result  Cytology result  
  Low grade* 
(n = 47) 
n (%) 
High grade** 
(n = 26) 
n (%) 
Total 
(n = 73) 
n (%) 
 
Negative  14 (29.8) 10 (38.5) 24 (32.9)  
Low grade***  26 (55.3) 8 (30.8) 34 (46.6)  
High grade****  7 (14.9) 8 (30.8) 15 (20.5)  
Total   47 26 73  
% of total   64.4 35.6 100.0  
 
Notes: Somers’ D p = 0.790. 
 
*Low grade cytology includes ASCUS no HPV result, ASCUS HPV positive, ASCUS 
HPV negative, and LSIL. 
**High grade cytology includes HSIL, AGC, ASCUS-H, and LSIL-H. 
*** Low grade histology includes Cervicitis, CIN I. 
****High grade histology includes CIN II, CIN III, CIS, invasive neoplasia, 
adenocarcinoma. 
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Table 4-7. Crosstabulation of collapsed cytology and histology result for any 
progesterone exposure (n = 108) 
Histology result  Cytology result  
  Low grade* 
(n = 78) 
n (%) 
High grade** 
(n = 30) 
n (%) 
Total 
(n = 108) 
n (%) 
 
Negative  24 (34.3) 13 (34.2) 37 (34.3)  
Low grade***  39 (55.7) 11 (28.9) 50 (46.3)  
High grade****  7 (10.0) 14 (36.8) 21 (19.4)  
Total  78 30 108  
% of total  64.8 35.2 100.0  
 
Notes: Somers’ D p = 0.131.  
 
*Low grade cytology includes ASCUS no HPV result, ASCUS HPV positive, ASCUS 
HPV negative, and LSIL. 
**High grade cytology includes HSIL, AGC, ASCUS-H, and LSIL-H. 
*** Low grade histology includes Cervicitis, CIN I. 
**** High grade histology includes CIN II, CIN III, CIS, invasive neoplasia, 
adenocarcinoma. 
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Research Question 3: Is There a Difference in the Relationship between Cytology 
and Histology in Four Groups of Women with Abnormal Cytology Results? 
 Table 4-8 reports agreement between cytology and histology results by 
progesterone exposure. Chi square analysis was performed χ² (2, n = 180) = 0.5, 
ρ = 0.781. No difference in the association between cytology and histology by 
progesterone exposure was noted. 
Table 4-9 breaks down the disagreement rates further into the finer levels of 
either false positive or false negative effect. A false positive effect (defined as the 
cytology result overestimating the severity of the cervical cells when judged against 
histology results) was noted among 52.8% of the non-hormonal/no contraception group, 
51.4% of the progesterone IUD group, 47.9% of the progesterone injection group, and 
49.1% of the group combining the two progesterone methods. A false negative effect 
(defined as the histology result being more severe than the cytology result) was noted in 
5.6% of the non-hormonal/no contraception group, none of the IUD group, 9.6% of the 
injection group, and 6.5% when the two progesterone method groups were combined. A 
false negative effect was rare at less than 10% for any of the categories. No significant 
association between type of progesterone exposure and level of agreement (agree, false 
negative, false positive) was noted (p =  0.83); χ² (1, n = 180) = .05. 
The association between cytology and histology results was tested by the use of 
Chi Square statistics. Table 4-10 shows no difference in association between cytology to 
histology results by progesterone exposure (none, IUD or injection) (p =  0.781); χ² (2, 
N = 180) = 0.5. Table 4-10 also shows no difference in association by level of agreement 
(either agree/disagree) between cytology to histology (p =  0.83) by either any 
progesterone exposure as compared to none, with χ² (1, N = 180) = .05. No difference in 
association between cytology and histology was noted (p =  0.396); χ² (4, N = 180) = 4 
after breaking down the disagreement level into two sub-levels of disagreement (false 
positive or false negative) by progesterone exposure per group (IUD, injection, or none). 
Finally, no difference in association between cytology and histology was noted when 
analyzing degree of agreement between cytology and histology by sub-levels of false 
negative or false positive, by any progesterone exposure (IUD or injection) versus no 
progesterone exposure (p =  0.88); χ² (2, N = 180) = 0.26. 
Research Question 4: Is There a Difference in the Relationship between  
Cytology and Histology, by Length of Time Using Either Depot 
Medroxyprogesterone Acetate or Progesterone IUD? 
 Two logistic regressions were undertaken to address this question in which the 
variables length of time using progesterone, age, group (whether IUD or injection), and 
group by time using progesterone were analyzed for interaction. The logistic regression 
model, roughly analogous to the multiple linear regression, allows for analysis with 
dichotomous variables. The logistic regression models allowed for testing whether there 
was a relationship between time on progesterone and the relationship between cytology 
and histology.  The first regression model analyzed progesterone in the context of agree
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Table 4-8. Agreement between cytology and histology results by progesterone exposure 
Agreement 
 
 
 
Non-hormonal or 
no contraception 
(n = 72) 
n (%) 
Progesterone 
IUD 
(n = 35) 
n (%) 
Progesterone 
injection 
(n = 73) 
n (%) 
Combined IUD 
and injection       
(n = 108) 
n (%) 
Total 
(n = 180) 
n (%) 
Agree  30 (41.7) 17 (48.6) 31 (42.5) 48 (44.4) 78 (43.3) 
Any 
disagreement 42 (58.3) 18 (51.4) 42 (57.5) 60 (55.6) 102 (56.7) 
Total 72 (100) 35 (100) 73 (100) 108 (100) 180 (100) 
 
Notes: χ² (2, n = 180) = 0.5, ρ = 0.781.  
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Table 4-9. Agree, false negative, or false positive results between cytology and histology by progesterone exposure 
Agreement 
 
 
 
Non-hormonal or 
no contraception 
(n = 72) 
n (%) 
Progesterone 
IUD 
(n = 35) 
n (%) 
Progesterone 
injection 
(n = 73) 
n (%) 
Combined IUD 
and injection       
(n = 108) 
n (%) 
Total 
(n = 180) 
n (%) 
Agree 30 (41.7) 17 (48.6) 31 (42.5) 48 (44.4) 78 (43.3) 
False positive 38 (52.8) 18 (51.4) 35 (47.9) 53 (49.1) 91 (50.6) 
False 
negative 4 (5.6) 0 (0.0) 7 (9.6) 7 (6.5) 11 (6.1) 
Total 72 (100) 35 (100) 73 (100) 108 (100) 180 (100) 
 
Note: χ² (1, n = 180) = .05. 
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Table 4-10. Tests of the cytology/histology relationship and progesterone exposure 
Table structure and variable 
encoding 
Chi-square 
(df) ρ -value 
Bonferroni-adjusted multiple 
comparisons of agreement/concordance 
rates between progesterone groups* 
Cytology/histology agreement (agree, 
disagree) by progesterone exposure 
(none, IUD, injection) 
0.495 
(2) 0.781 (None significant) 
Cytology/histology agreement (agree, 
disagree) by progesterone exposure 
(any [IUD or injection], none) 
0.046 
(1) 0.830 (None significant) 
Cytology/histology agreement (agree, 
false positive, false negative) by 
progesterone exposure (none, IUD, 
injection) 
4.075 
(4) 0.396 (None significant) 
Cytology/histology agreement (agree, 
false positive, false negative) by 
progesterone exposure (any [IUD or 
injection], none) 
0.255 
(2) 0.880 (None significant) 
 
Notes: χ² (2, N = 180) = 0.5. 
 
*Are only relevant if the Chi-Square test is statistically significant. 
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(yes/no), and the second in the context of false positive (yes/no). In the omnibus test of 
the first model, χ² (4, n = 108) = 4.95, p = 0.29. The omnibus test of the second model 
noted χ² (4, n = 108) = 4.08, p = 0.40. No relationship between time of progesterone 
exposure and accuracy of cytologic interpretation was noted, which is congruent with the 
finding that there was no difference in relationship between the groups regardless of 
progesterone exposure or type. 
Post Hoc Power Analyses 
 A post hoc power analysis was run to determine the power in the study. The 
analyses were based on observed effect sizes, and were run on each of the four Chi 
square analyses with criterion set at .05 (two tailed) test. Results are shown in Table 
4-11. The effect size for the first Chi square analysis was .05. With the sample size of 180 
the study will have power of 9% to yield a statistically significant result. Total number of 
cases to detect an effect of this size with 80% power at the .05 alpha level would be 
3,542.  
 Power analysis on the second Chi square analysis revealed an effect size of .02. 
With the sample size of 180 the study will have power of 6% to yield a statistically 
significant result. Total number of cases to detect an effect of this size with 80% power at 
the .05 alpha level would be 20,062.  
 Power analysis on the third Chi square analysis revealed an effect size of .16. 
With the sample size of 180 the study will have power of 36% to yield a statistically 
significant result. Total number of cases to detect an effect of this size with 80% power at 
the .05 alpha level would be 471.  
 Power analysis on the fourth Chi square analysis revealed an effect size of .05. 
With the sample size of 180 the study will have power of 9% to yield a statistically 
significant result. Total number of cases to detect an effect of this size with 80% power at 
the .05 alpha level would be 3,809.   
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Table 4-11. Post hoc power analyses 
Model Observed  
effect size 
Power to yield 
stat. sig. result % 
Total number of cases 
to detect effect 
1st .05 9 3,542 
2nd .02 6 20,062 
3rd .16 36 471 
4th .05 9 3,809 
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CHAPTER 5. DISCUSSION 
The purpose of this study was to examine the accuracy of cervical cytologic 
findings in women who were using either one of two forms of progesterone only 
contraception, depot medroxyprogesterone acetate injection or the progesterone IUD, as 
compared to women who either used a non-hormonal form of contraception or no 
contraception at all. This section will first review the relationship between factors such as 
race and socioeconomic status on a woman's decision to use one of the progesterone 
methods studied. Next, an exploration into the study population characteristics (smoking 
status, marital status, obstetrical history) is undertaken. Third, the relationship between 
cytology and histology according to progesterone exposure, and then the differences in 
that relationship, are explored. Last, significance of the findings, study limitations, and 
conclusions are discussed.   
Use of Contraception Method 
There was a higher percentage of black subjects (64%) compared to white 
subjects (28.8) who used the progesterone injection. This finding is consistent with other 
studies showing that 84% of progesterone injection users are black.34,35,90 A greater 
percentage of white subjects (54.3%) than black subjects (28.6%) used the progesterone 
IUD. Socioeconomic status was not obtained in this study.  
 
A patient's race/ethnicity and socioeconomic status have been shown to be factors 
in a practitioner's decision of recommendation for type of contraception,35 which may 
account for why more white women than black women were using intrauterine 
contraception. Dehlendorf et al. (2010)35 noted in their study on provider 
recommendations for intrauterine contraception that white women of low socioeconomic 
status were significantly less likely than white women of high socioeconomic status to 
have intrauterine contraception recommended to them by their providers. Race did not 
have bearing on provider recommendation among women of high socioeconomic status. 
A 2007 study noted 74% of progesterone injection users were of low socioeconomic 
status.90 Progesterone injections are far less costly at the point of service than intrauterine 
devices at initiation ($35 - $75 average cost per injection versus $500 to $1000 at the 
time of insertion for IUD).92 Cost at initiation may underscore the rationale why women 
of lower socioeconomic means actually choose the progesterone injection. Providers may 
not offer the IUD to women of lower socioeconomic means because there is an 
assumption that it would be unaffordable for them. However, IUD device and insertion 
costs are generally covered equally as well as the progesterone contraceptive injection, so 
why this thought exists cannot be thoroughly explained. The aspect of economic status 
and effect on provider recommendation for contraception was not explored in this study. 
Age has also been shown to have bearing on usage of progesterone injection as 33% of 
progesterone injection users are noted to be under the age of 19.34 
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Smoking Status 
The total sample had higher smoking rates than would be observed in a random 
sample population. The percentage of smokers in the study sample (30.6%) was higher 
than that noted in the general population of females in the geographical area in Tennessee 
(23.7%)27 The smoking statistic for women in general in Tennessee is higher than the 
percentage of smokers noted in the non-hormonal/no contraceptive use group (22%), but 
lower than the rates noted for the IUD users (25.7%), the injection users (41.1%), the 
combined injection or IUD group (36.1%), or the overall smoking rate (30.6%) which 
included all subjects. The study subjects were located in the geographic area of Middle 
Tennessee, where the most current reported smoking statistics noted a 25.3% smoking 
prevalence among whites, and a 23.9% prevalence among blacks (statistics included both 
men and women). Black females living in Tennessee have been noted to have the lowest 
prevalence of smoking, at 19.5%.27 The rates for smoking among the study subjects were 
highest in the progesterone injection group (41.1%) and lowest in the non-hormonal/non 
contraceptive group (22.2%).  
The finding that there was a higher percentage of smokers among the 
progesterone injection group is not consistent with established findings on either race, or 
adolescence and smoking. Current information on trends in smoking across races in adult 
women107 show the highest prevalence rate of smoking among American Indian women 
(22.4%) followed by whites (20.6%), then blacks (17.8%), Hispanic (10.7%) and Asians 
(4.7%). The fact that the progesterone injection group contained more smokers was 
unexpected, given that the progesterone group was comprised largely of black women. 
There is not an obvious explanation for this difference, and is therefore an issue for 
further investigation. The progesterone injection group may have contained more 
adolescents and young adults than the other two groups. Davis, Nonnemaker, Asfaw, and 
Vallone (2010)108 reported on both perceived and actual smoking rates among 
adolescents in the U.S. The perception among study subjects was that American Indian 
adolescents had the highest smoking rates (48.4%) followed by black adolescent females 
(46.6%), followed by Hispanic (44.2%), than white (37.4%), then Asian (32.4%) 
adolescents. However, the actual smoking rates among adolescents were quite different at 
15.8% for American Indian adolescents, followed by 10.5% of white adolescents, 9.6% 
of Hispanic adolescents, 6.2% of black adolescents, and lastly, 5.4% of Asian 
adolescents. Two other studies have demonstrated that black adolescents are less likely to 
smoke than white adolescents.109,110 Data suggest, however, that this pattern is altered in 
late adolescence and early adulthood in that black adults have a higher smoking 
prevalence rate when compared with other racial/ethnic groups.   
The variations may be the result of differences in socioeconomic determinants 
(e.g. marital status, education, and race/ethnicity) of smoking, as well as differing social 
norms regarding tobacco use in the geographic area where the study was conducted. 
Socioeconomic status was not collected for the purposes of this study. Numerous studies 
have confirmed that socioeconomic factors have an influence on smoking prevalence. 
Adult smoking prevalence is greater among those of lower socioeconomic status.111-113 
Socioeconomic status was not collected for the purposes of this study, yet Davidson 
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county, which encompasses the largest area where the subjects resided, has 17.1% of 
residents living below poverty level, with a mean income of $46,249.26 (U.S. Census 
Bureau, 2011). The Tennessee Department of Public Health reported that prevalence of 
smoking was lowest among those earning $75,000 or more (at 13.3%), and highest 
among those whose household incomes were less than $25,000 annually (at 35.8%).27  
Numerous papers have documented the enhanced mutagenic effect of HPV 
infected cervical cells exposed to smoking, whether by primary or second hand smoking 
exposure.8,9,25,28,47,48,114-118 Elevated tobacco and nicotine by-products, specifically 
cotinine, concentrate in cervical mucus and accelerate the progression rate of developing 
squamous intraepithelial dysplasia and neoplasia. The process of DNA damage 
attributable to the tobacco product and by products is directly caused by the interruption 
of p53 and pRb gene paths via the over expression of the E6 and E7 viral oncogenes.53 
Nicotine levels in the cervical mucus of female smokers with cervical intraepithelial 
neoplasia have been noted to be 40 fold that of serum levels.50  
Smoking may enhance development of cervical dysplasia via weakening of the 
immune system. The HPV infection is allowed to persist within the cells, leading to 
dysplasia and neoplasia in someone with less than optimal immune system protection to 
clear the virus.114,119 Langerhans' cells, with their macrophage like behavior, have been 
noted to be present in far less concentration in the cervical epithelium of female 
smokers.120 Smoking has an accelerator effect on both cellular metaplasia, and mitosis.8  
Existing information regarding the effect of smoking on HPV infected cervical 
cells supports the finding of higher frequency rates of smoking among those women in 
this study. The positive association between smoking and cervical dysplasia underscores 
the greater incidence of smokers among the subjects in this study.  By comparison, 
similar rates of tobacco use have been noted among study subjects in similar studies. 
Tobacco usage rate reported among premenopausal study subjects by Moore et al. was 
49%, and 36% among menopausal women, in their study of 359 women presenting to the 
colposcopy clinic.39 Coker et al. (2002)121 reported the following smoking rates among 
women with HSIL cytology results: 36% reported that they had ever smoked, with 31% 
currently smoking and 5% former smokers. Women with LSIL Pap results reported 
having ever smoked 34% of the time, while 24% currently smoked, and 9% were former 
smokers.121 
Moscicki et al. (2008)122 reported the following smoking rates among their study 
sample of adolescents and young women: 27.4% of those with CIN I or less were current 
smokers, 30.9% of those with CIN 2 were current smokers, and 36.6% of those with CIN 
3 were current smokers.122 Women with minimally abnormal cytology results (N = 
5,060) had a 35% current smoking status prevalence, and a 12 % former smoking status 
prevalence.80 A population based case control study conducted in Spain and Columbia 
noted smoking rates consistent with those in studies conducted in the US. Bosch et al. 
(1992)87 noted among their study population, that 26.4% in Spain, and 50.5% in 
Columbia had ever smoked (encompassing former and current smokers), while only 
16.8% of the control group in Spain had smoked, and 40% of the Columbian control 
group had ever smoked.87  
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Another reason that the smoking rates could have been higher in this sample was 
the fact that female smokers are less likely to seek out regular cervical neoplasia 
screening.57,58,69 Dysplasia may be detected earlier, and if necessary, treated, with regular 
cervical neoplasia screening, which would result in subsequent cytology findings 
returning as normal. Time from prior screening to collection of abnormal Pap result was 
not collected on the subjects in this study. Future research should include this variable 
since delaying screening would allow time for cervical cells to continue to change and 
move to a high enough level of abnormality to be present in the cytological result.  
Marital Status 
The largest percentage of married women was in the IUD group, and the lowest 
percentage of married women was in the progesterone injection group. Clinical 
recommendations regarding appropriate IUD candidate selection excluded women who 
were not in a mutually monogamous relationship, until very recently, which could largely 
explain the greater number of married women who had the IUDs in situ.123 Only very 
recently have recommendations changed to allow inclusion of women who have multiple 
partners to be candidates for IUD placement.94 The pattern of use noted in this study 
group does correspond with the pattern of IUD use noted in the general population.94 
Obstetrical History 
The progesterone injection group contained the largest percentage of nulligravid 
women (16.4%) and the IUD group contained the lowest percentage of nulligravid 
subjects (11.4%). This is consistent with practice trends.124 Nulligravid women have only 
recently begun to be included as appropriate candidates for IUD placement. Historically 
IUDs were not inserted into a nulligravid woman because of the theoretical increased risk 
between pelvic inflammatory disease (PID) and IUD use. The widespread thought has 
been that there was an increased risk of PID among IUD users, and PID is a risk factor 
for female infertility. Thus, practitioners did not place IUDs in nulligravid women.124 The 
link between PID and IUD use has been clarified and nulligravid women have been 
deemed appropriate candidates for IUD placement.91 There will be a lag period of time  
before that paradigm shift is reflected in statistics demonstrating IUD usage by 
gravida/parity, because of the lag in time between change in recommendation, and actual 
observation of that change in clinical practice,.  
  Observed Frequency of Abnormal Pap Results  
 Frequency of the various cytologic abnormalities was similar across the groups. 
The prevalence of HSIL cytology results was greater among the study population 
(23.3%) as compared to what has been observed in other studies. Clark et al. (2011) noted 
the following prevalence of abnormalities in their study, in order from most to least 
prevalent: LSIL (44.4%), ASCUS, which included all designations of ASCUS (38.7%), 
HSIL (8.6%) and AGC (8.6%).36 Hoekstra et al. (2006)104 noted the following breakdown 
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of cytology classification abnormality in their study: ASCUS, which included all 
designations of ASCUS (12.8%), LSIL (9%), HSIL (6%), AGC (1%).104 Variation in 
prevalence of type of cytology may vary by risk factors of participant groups in various 
studies, as well as inclusion of pregnant or menopausal women (both were excluded from 
this study). Inclusion of post-menopausal women, representing a hypoestrogenic state, 
and pregnant women, representing a hyperestrogenic state, could affect the observed 
frequency of the various reported abnormalities.  
Relationship between Cytology and Histology According to 
 Progesterone Exposure   
There was a significant relationship between cytology and histology overall 
(p = .008). This confirms what is well known about the cytology/histology relationship. 
Specifically, multiple studies have noted the strong positive association between 
cytologic screening and histologic diagnosis in detecting cervical dysplasia.13,14,125  
There was a significant association between cytology and histology (p = .019) 
among women who had no progesterone exposure (Table 4-3). This again would be 
expected, based on what is known in the literature. There was a significant association 
between cytology and histology among women using the progesterone IUD (p = .019) 
(Table 4-4). This again is consistent with what exists in the literature regarding cytologic 
and histologic association.  
There was not a significant association between cytology and histology findings 
among progesterone injection users (p =  .790) (Table 4-5). This finding is not consistent 
with the prior analyses in this study of no progesterone exposed subjects, IUD users and 
the entire study group overall. However, these initial analyses are subgroup analyses 
which use only the low grade/high grade concept of defining the cytology/histology 
relationship. Analysis using only the low grade/high grade concept does not address the 
nuances in the cytology/histology relationship of those false negative and false positive 
situations which occur within the realm of the low grade/high grade relationships. The 
more precise approach to agreement used in further analysis clarifies to a greater degree, 
this question of agreement noted in this analysis. This analysis result is important, 
however, because it provides the impetus to look further into the relationship between 
cytology and histology in women using the progesterone injection for contraception, 
particularly because this relationship differs from the relationship between cytology and 
histology noted between women not exposed to any exogenous hormones. 
No significant relationship between cytology and histology findings was found 
among subjects with any progesterone exposure (whether IUD or injection) (p = .131) 
(Table 4-6). This finding is not consistent with those analyses run on the entire study 
population, any progesterone exposure groups, and the IUD group. When only the low 
grade/high grade concept of defining the cytology/histology relationship is used, there is 
room for error in overlooking the false negative and false positive findings that occur 
within the various cytology/histology relationships.  
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Prior studies examining the effect of progesterone only contraception on the 
cytologic/histologic relationship did not provide a defining outcome variable, as was 
provided in this study. The ability to determine not only agreement/disagreement, but the 
level of that disagreement, captures those subtleties in the relationship between cytology 
and histology that would be lost if the level of disagreement was not defined. The 
conclusion that cytologic interpretation is affected by progesterone exposure could be 
drawn if analysis ceased at the level of agree/disagree. The new defining outcome 
variable enables a deeper level of analysis where the issue can be more discreetly 
defined.  
Chi square analysis of the relationships between cytology and histology for any 
progesterone exposure (which would be the combined groups of the IUD and the 
injection) noted a non-significant association between cytology and histology (p = 0.13) 
(Table 4-7). Subgroup analyses that use only the low grade/high grade concept, because 
they do not address the subtleties the groups, may miss the between false negative and 
false positive situations which occur within the low grade/high grade realm of possible 
cytology/histology combinations.  
Difference in Relationship between Cytology and Histology According to 
Progesterone Exposure 
 The first Chi square analysis was done to address the question, whether the 
cytology/histology relationship could be classified as an agree situation (either yes or no) 
across each of the groups individually (the non-hormonal/no contraception group, the 
IUD group, and the injection group). The rates of agree, either yes or no, were very 
similar across groups. There was no significant association between progesterone 
exposure by type and level of agreement by the two levels of either agree/disagree 
(p = .781). The second analysis done to address this question grouped the two 
progesterone exposed groups together. The purpose of this analysis was to evaluate the 
relationship of cytology to histology by either no progesterone exposure (the non-
hormonal/con contraception use group) or any progesterone exposure (the IUD and 
injection groups together). The percent of agreement, either yes or no, is very close 
between the progesterone and non-progesterone exposed groups. There was no difference 
in association between cytology and histology (p = 0.83) in this second analysis, by 
either any progesterone exposure (i.e. IUD and injection groups combined) or no 
progesterone exposure. 
The level of agreement was broken down further in the third analysis run to 
address this question, Each group was analyzed by progesterone exposure (either none, 
IUD or injection) in this analysis by either agree, or if no, then whether false negative or 
false positive. Of note, a false negative relationship was noted very rarely, at less than 
10% for any of the groups. The finding that a false negative relationship was noted rarely 
is reassuring, in that the incidence of cytologic screenings underestimating clinical 
situations wherein women have a much greater degree of pathology is extremely low. No 
significant association was found (p =  0.83) between type of progesterone exposure and 
agreement by the levels of agree, false negative, or false positive.  
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The level of agreement used was the agree, false negative or false positive, newly 
defined outcome variable in the fourth and final analysis run to address this question. The 
analysis examined the relationship of cytology to histology by either any progesterone 
exposure (the IUD and injection groups combined), or no progesterone exposure (the 
non-hormonal or no contraception group). No significant difference in association 
between cytology and histology was found (p =  0.88) by any progesterone exposure.. 
There was no significant difference in  association between cytology and histology by 
progesterone exposure, nor significant difference in agreement between cytology and 
histology by progesterone exposure.  
The findings in this study are congruent with the findings of Zhu & Wilbur 
(1998),100 who noted no significant increase in the rate of ASCUS preceeded squamous 
intraepithelial lesions among progesterone users. The study findings are also consistent 
with those of Hoekstra et al (2006), who noted that the rate of false-positive cytologic 
screening results was not different among hormone exposed women (either the 
progesterone injection, progesterone implant, or combined oral contraception) as 
compared to non hormone exposed women.104 These study findings are also congruent 
with those of Darwish et al. (2004), who noted no increase in abnormal cytologic results 
among progesterone contraception users.103 Most recently, Clark et al. (2011), also noted 
similar findings in their study of false-positive l cervical cytology results among women 
using either progesterone only or combined contraception.36 
Relationship between Cytology and Histology, by Length of Time Using either 
Depot Medroxyprogesterone Acetate or Progesterone IUD 
 Two logistic regressions were undertaken in which the variables of time on 
progesterone, age, group (IUD or injection), and group by time on progesterone were 
analyzed for interaction. The outcome in logistic regression is dichotomous (agree or 
disagree) (false positive or not false positive). The logistic regression models allowed a 
test of (after adjusting for age) whether there was a relationship between time on 
progesterone and the type of progesterone delivery system on the dichotomous outcome. 
The two regressions demonstrated that the models for either regression were not stellar 
(by Omnibus test of model coefficients). No relationship between time of progesterone 
exposure and accuracy of cytologic interpretation was noted, which is congruent with the 
finding that there was no difference in relationship between the groups regardless of 
progesterone exposure or type.  
 The first analysis examined the relationship between cytology and histology in the 
context of agree (yes or no). Model 1 was designed to test the effect of time on 
progesterone and mode of progesterone delivery on the likelihood of agreement between 
cytology and histology findings controlling for age. Additionally, an interaction term of 
time by progesterone delivery mode was included to test whether there was a difference 
in the relationship between the length of progesterone exposure and the likelihood of 
agreement on the basis of either progesterone mode of delivery. An investigation on the 
variable of time on a non- significant relationship may not have been necessary. 
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 The effect of duration of exposure to progesterone was not significant (p =  
0.107). There was no evidence of an association between duration of progesterone 
exposure and the likelihood of a false positive finding. Both of these regressions 
supported the findings from the analysis of research questions 2 and 3, which 
demonstrated that progesterone exposure was not associated with a difference in the 
proportions of patients having agreement, false negative or false positive findings. 
Significance of Findings  
Although our exploratory study was significantly underpowered, findings suggest 
that the subjects in this study who used either the progesterone IUD or injection had no 
difference in association of their cytology to histology findings compared to women who 
had no progesterone exposure and further study is needed to confirm these results. Also 
there is a greater degree of prevalence of smoking among the women in the study with 
abnormal cytology results, as compared to the smoking rates among the general 
population. Research should continue to be aimed at investigation of the additive effect of 
smoking on dysplasia rates in women infected with HPV.  
Areas for future research include analyzing other disease processes in women 
who both smoke and use progesterone only contraception. Investigating whether there are 
differences in morbidity and mortality rates for progesterone exposed women who have 
chronic diseases such as osteoporosis and coronary artery disease has been understudied. 
Also, since coronary artery disease remains the primary cause of mortality in 
women126,127 investigation of any exogenous hormonal association to coronary artery 
disease is an important research topic. Further investigation into the aspects of morbidity 
and mortality associated with acute myocardial effects in women exposed to progesterone 
is a focused area of cardiac health research that necessitates further research.  
This study analyzed two forms of progesterone only contraception, but there are 
multiple other forms of progesterone that have not been studied to determine if there is an 
effect on the relationship between cytology and histology. Oral progesterone only pills 
and implantable forms of progesterone, such as the relatively new implantable mode, 
etonogestrel subdermal implant (Implanon®), are two forms that have not been evaluated 
critically for any effect on cervical cells. The delivery mode of progesterone in this study 
was either systemic (the injection) or local (the IUD). Other delivery modes may have 
varying effects on cervical cells, and thus may affect cytological interpretation accuracy 
differently than those modes included in this study.  
Another important issue related to research in this area is that the prevalence of 
various high risk HPV types varies among populations and countries.5,81 Repeating this 
study among populations with different high risk HPV type prevalence may reveal 
associations not detected in this study. Also, analyzing for effect difference among 
varying population groups would be of value. The proportion of Hispanic and Asian 
subjects in this study was small. Repeating the study among those particular populations 
may reveal additional information not detected in the current study. Lastly, the 
progesterone IUD is used more widely in Europe than in North America (1-2% in the 
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U.S. versus as high as 24% in some European countries).124 Repeating the study in a 
geographic area with a higher progesterone IUD usage rate would likely yield a larger 
sample of IUD users than was obtained in this study.  
Limitations 
A primary limitation of this study was that there was a threat to the internal 
validity. The inability to control for either the same practitioners collecting the samples, 
or the same pathology professionals interpreting the samples could be seen as a 
limitation. The study undertook the examination of existing cytologic and histologic 
reports contained within the subjects’ records. There was no way to assure that all the 
various practitioners or pathology professionals followed exactly the same standard as 
they provided their clinical services.   
Another limitation of the study involved the use of an electronic database used for 
the data. Data, particularly demographic data, may have been missing from patient 
records. In addition, patient records are heavily reliant on the information first being 
correctly entered by patient care providers. However, this large database was an ideal 
medium to use for this particular study because of both the volume and heterogeneity of 
the subjects.  
A limitation of the study was that a much larger sample size would be necessary 
to be able to draw conclusions from this study because of the lack of power that was 
calculated after the data analysis. Only 2% of US women use IUD devices,128 and a 
portion of those will have used the copper IUD rather than the progesterone IUD. The 
progesterone IUD subjects were anticipated to constitute the smallest number of subjects. 
One suggestion for future research would be replicating the study in a country outside of 
the US where the progesterone IUD has much wider usage. Further, the study subjects 
were all residents of one geographical urban area, with very few subjects from some 
racial groups, particularly Latino and Asian women.  
Conclusion 
Accuracy of cytologic interpretation is necessary for the appropriate treatment of 
women with cellular dysplasia or neoplasia. Factors which ostensibly could alter the 
accuracy of cytologic interpretation need to be identified and explored. Investigating 
factors which have potential to affect cytologic interpretation is important because of the 
potential for adverse physical and psychological affects in women given abnormal 
cytology results. Inaccurate results also lead to unnecessary follow up procedures and 
unnecessary costs. Exogenous progesterone affects cervical cellular characteristics, 
though the result of this effect on the accuracy of cervical cytologic interpretation is less 
clear. Little research has been conducted on whether the cellular changes related to 
progesterone alter the accuracy of cytological interpretation, and what has been done to 
date has had incongruent findings. Conducting this type of research study on 
progesterone contraceptive exposure and potential cervical cytologic changes is 
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challenging for many reasons. First, a retrospective study design is the most feasible to 
use because only subjects with abnormal cytology test results are included. Second, 
obtaining a sample set of subjects who have an abnormal cytology result, with subsequent 
biopsy result and who also use a progesterone IUD is difficult because the usage rate of 
the progesterone IUD is lower in the U.S. than it is in many other countries. However, 
even considering the difficulties of conducting this type of study, the accuracy of 
cytologic interpretation is necessary to the appropriate treatment of women who have 
cellular dysplasia or neoplasia.  
No significant association was found between progesterone contraception 
exposure and difference in accuracy of cytologic interpretation as compared to women 
with no progesterone contraception exposure. Additionally, no effect was noted between 
time of progesterone exposure and difference in agreement between cytology and 
histology. This study was the first to analyze the effect of the progesterone IUD versus 
the progesterone injection on the cytology/histology interpretation relationship. 
Comparison between IUD and progesterone injection was important because of the 
difference in delivery of the hormone (local with the IUD versus systemic with the 
injection).  
This study was underpowered, but there is potential for conducting a similar 
study. The challenge would be in recruiting enough subjects to achieve power. A future 
study would very likely have to be a multi-center, multi-site study in order to recruit 
enough subjects with abnormal cytology results and who also used progesterone only 
contraception. Including countries outside of the U.S. would also very likely need to be 
considered, and would give a much richer sample. The recruiting of subjects from 
international sites who use varying types of contraception, and have varying sexual 
behavior patterns is a recommendation for future research. 
Another recommendation for future research is to look into the various evaluation 
systems with which cells are interpreted by pathology professionals, and how those scales 
affect cellular interpretation. Studies included in this review of literature used varied 
methods of gradation in evaluating the maturation of cells. The use of different 
measurement scales may lead to some inconsistency across studies in both interpretation 
and evaluation of interpretation rates. Lastly, alternate forms of progesterone (implant 
and oral progesterone formulation) may also have varying effect on this phenomenon. 
Future studies could examine some of the other forms of progesterone to determine if the 
delivery system of progesterone has any effect on cervical cytology interpretation.  
Cervical cytologic screening is the most efficacious way of detecting cervical 
neoplasia currently available. Any factor that could interfere with the accuracy of 
cytologic interpretation should be identified. Women at risk for cervical neoplasia should 
be made aware of any effects that exogenous hormones may have on the accuracy of 
cytologic interpretation, so that they can make informed choices regarding their 
contraception methods. Though this study did not reveal a relationship between either of 
the two forms of progesterone and interpretation differences when compared to non-
progesterone users, the results have limited utility due to small sample size and 
inadequate power. What can be derived from the study is a basis for comparing varied 
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progesterone delivery systems, as well as format for repetition of a similar study in a 
multi center, multi site study.  
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